Requirement	O
for	O
p38	B-protein
and	O
p44/p42	B-protein
mitogen-activated	B-protein
protein	I-protein
kinases	I-protein
in	O
RAGE	B-protein
-mediated	O
nuclear	B-protein
factor-kappaB	I-protein
transcriptional	O
activation	O
and	O
cytokine	O
secretion	O
.	O

Advanced	O
glycation	O
end	O
product	O
(	O
AGE	O
)	O
activation	O
of	O
the	O
signal-transducing	B-protein
receptor	I-protein
for	I-protein
AGE	I-protein
(	O
RAGE	B-protein
)	O
has	O
been	O
linked	O
to	O
a	O
proinflammatory	O
phenotypic	O
change	O
within	O
cells	O
.	O

However	O
,	O
the	O
precise	O
intracellular	O
signaling	O
pathways	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
demonstrate	O
here	O
that	O
human	O
serum	O
albumin	O
modified	O
with	O
N	O
(	O
varepsilon	O
)	O
-	O
(	O
carboxymethyl	O
)	O
lysine	O
(	O
CML	O
)	O
,	O
a	O
major	O
AGE	O
adduct	O
that	O
progressively	O
accumulates	O
with	O
aging	O
,	O
diabetes	O
,	O
and	O
renal	O
failure	O
,	O
induced	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
-driven	O
reporter	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
THP-1	I-cell_type
cells	I-cell_type
.	O

The	O
NF-kappaB	O
response	O
was	O
blocked	O
with	O
a	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
putative	B-protein
ligand-binding	I-protein
domain	I-protein
of	O
RAGE	B-protein
,	O
with	O
anti-	O
RAGE	B-protein
antiserum	O
,	O
and	O
by	O
coexpression	O
of	O
truncated	B-protein
receptors	I-protein
lacking	O
the	O
intracellular	B-protein
domain	I-protein
.	O

Signal	O
transduction	O
from	O
RAGE	B-protein
to	O
NF-kappaB	B-protein
involved	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
,	O
since	O
reporter	O
gene	O
expression	O
was	O
blocked	O
with	O
the	O
antioxidant	O
N-acetyl-L-cysteine	O
.	O

CML-modified	B-protein
albumin	I-protein
produced	O
rapid	O
transient	O
activation	O
of	O
tyrosine	O
phosphorylation	O
,	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
,	O
but	O
not	O
c-Jun	B-protein
NH	I-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
kinase	I-protein
.	O

RAGE	B-protein
-mediated	O
NF-kappaB	O
activation	O
was	O
suppressed	O
by	O
the	O
selective	O
p38	B-protein
MAPK	I-protein
inhibitor	O
SB203580	O
and	O
by	O
coexpression	O
of	O
a	O
kinase-dead	O
p38	O
dominant-negative	O
mutant	O
.	O

Activation	O
of	O
NF-kappaB	B-protein
by	O
CML-modified	B-protein
albumin	I-protein
increased	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-1beta	B-protein
,	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
)	O
severalfold	O
,	O
and	O
inhibition	O
of	O
p38	B-protein
MAPK	I-protein
blocked	O
these	O
increases	O
.	O

These	O
results	O
indicate	O
that	O
p38	B-protein
MAPK	I-protein
activation	O
mediates	O
RAGE	B-protein
-induced	O
NF-kappaB	B-protein
-dependent	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
and	O
suggest	O
that	O
accelerated	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
cellular	O
activation	O
induced	O
by	O
this	O
receptor	O
.	O

Requirement	NULL
for	NULL
p38	NULL
and	NULL
p44/p42	NULL
Mitogen-Activated	NULL
Protein	NULL
Kinases	NULL
in	NULL
RAGE-Mediated	NULL
Nuclear	NULL
Factor-KB	NULL
Transcriptional	NULL
Activation	NULL
and	NULL
Cytokine	NULL
Secretion	NULL
Chen-Hsiung	NULL
Yeh	NULL
,	NULL
'*	NULL
Lydia	NULL
Sturgis	NULL
,	NULL
``	NULL
Joe	NULL
Haidacher	NULL
,	NULL
'	NULL
Xue-Nong	NULL
Zhang	NULL
,	NULL
``	NULL
Sidney	NULL
J.	NULL
Sherwood	NULL
,	NULL
``	NULL
Robert	NULL
J.	NULL
Bjercke	NULL
,	NULL
``	NULL
Ondrej	NULL
Juhasz	NULL
,	NULL
``	NULL
Michael	NULL
T.	NULL
Crow	NULL
,	NULL
``	NULL
Ronald	NULL
G.	NULL
Tilton	NULL
,	NULL
``	NULL
and	NULL
Larry	NULL
Denner	NULL
'	NULL
Advanced	NULL
glycation	NULL
end	NULL
product	NULL
(	NULL
AGE	NULL
)	NULL
activation	NULL
of	NULL
the	NULL
signal-transducing	NULL
receptor	NULL
for	NULL
AGE	NULL
(	NULL
RAGE	NULL
)	NULL
has	NULL
been	NULL
linked	NULL
to	NULL
a	NULL
proinflammatory	NULL
phenotypic	NULL
change	NULL
within	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
precise	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
involved	NULL
have	NULL
not	NULL
been	NULL
elucidated	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
that	NULL
human	NULL
serum	NULL
albumin	NULL
modified	NULL
with	NULL
N°-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
(	NULL
CML	NULL
)	NULL
,	NULL
a	NULL
major	NULL
AGE	NULL
adduct	NULL
that	NULL
progressively	NULL
accumulates	NULL
with	NULL
aging	NULL
,	NULL
diabetes	NULL
,	NULL
and	NULL
renal	NULL
failure	NULL
,	NULL
induced	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-	NULL
«	NULL
B-driven	NULL
reporter	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
.	NULL

The	NULL
response	NULL
was	NULL
blocked	NULL
with	NULL
a	NULL
synthetic	NULL
peptide	NULL
corresponding	NULL
to	NULL
the	NULL
putative	NULL
ligand-binding	NULL
domain	NULL
of	NULL
RAGE	NULL
,	NULL
with	NULL
anti-RAGE	NULL
antiserum	NULL
,	NULL
and	NULL
by	NULL
coexpression	NULL
of	NULL
truncated	NULL
receptors	NULL
lacking	NULL
the	NULL
intracellular	NULL
domain	NULL
.	NULL

Signal	NULL
transduction	NULL
from	NULL
RAGE	NULL
to	NULL
NF-	NULL
<	NULL
B	NULL
involved	NULL
the	NULL
generation	NULL
of	NULL
reactive	NULL
oxygen	NULL
spe-cles	NULL
,	NULL
since	NULL
reporter	NULL
gene	NULL
expression	NULL
was	NULL
blocked	NULL
with	NULL
the	NULL
antioxidant	NULL
N-acetyl-L-cysteine	NULL
.	NULL

CML-modified	NULL
albumin	NULL
produced	NULL
rapid	NULL
transient	NULL
activation	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
1	NULL
and	NULL
2	NULL
,	NULL
and	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
,	NULL
but	NULL
not	NULL
c-Jun	NULL
NH	NULL
,	NULL
-terminal	NULL
kinase	NULL
.	NULL

RAGE-mediated	NULL
NF-	NULL
<	NULL
B	NULL
activation	NULL
was	NULL
suppressed	NULL
by	NULL
the	NULL
selective	NULL
p38	NULL
MAPK	NULL
inhibitor	NULL
S	NULL
$	NULL
B203580	NULL
and	NULL
by	NULL
coexpression	NULL
of	NULL
a	NULL
kinase-dead	NULL
p38	NULL
dominant-negative	NULL
mutant	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
CML-modified	NULL
albumin	NULL
increased	NULL
secretion	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
(	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
and	NULL
monocyte	NULL
chemoattractant	NULL
protein-1	NULL
)	NULL
severalfold	NULL
,	NULL
and	NULL
inhibition	NULL
of	NULL
p38	NULL
MAPK	NULL
blocked	NULL
these	NULL
increases	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
p38	NULL
MAPK	NULL
activation	NULL
mediates	NULL
RAGE-induced	NULL
NF-	NULL
«	NULL
B-dependent	NULL
secretion	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
and	NULL
suggest	NULL
that	NULL
accelerated	NULL
inflammation	NULL
may	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
cellular	NULL
activation	NULL
induced	NULL
by	NULL
this	NULL
receptor	NULL
.	NULL

Diabetes	NULL
50:1495-1504	NULL
,	NULL
2001	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
'Cell	NULL
Biology	NULL
and	NULL
Apoptosis	NULL
Program	NULL
and	NULL
the	NULL
``	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Texas	NULL
Biotechnology	NULL
Corporation	NULL
,	NULL
Houston	NULL
,	NULL
Texas	NULL
;	NULL
and	NULL
the	NULL
``	NULL
Laboratory	NULL
of	NULL
Cardiovascular	NULL
Science	NULL
,	NULL
National	NULL
Institute	NULL
on	NULL
Aging	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
.	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Larry	NULL
Denner	NULL
,	NULL
PhD	NULL
,	NULL
Department	NULL
of	NULL
Cell	NULL
Biology	NULL
,	NULL
Texas	NULL
Biotechnology	NULL
Corporation	NULL
,	NULL
7000	NULL
Fannin	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
.	NULL

E-mail	NULL
:	NULL
Idenner	NULL
@	NULL
tbe.com	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
7	NULL
July	NULL
2000	NULL
and	NULL
accepted	NULL
in	NULL
revised	NULL
form	NULL
15	NULL
March	NULL
2001	NULL
.	NULL

C.-H.Y	NULL
.	NULL

,	NULL
LS	NULL
.	NULL

,	NULL
JH	NULL
.	NULL

,	NULL
X-N.Z	NULL
,	NULL
,	NULL
SJ.S	NULL
.	NULL

,	NULL
R.J.B	NULL
.	NULL

,	NULL
R.G.T	NULL
.	NULL

,	NULL
and	NULL
LD	NULL
.	NULL

are	NULL
stock	NULL
share-holders	NULL
.	NULL

CML-HSA	NULL
,	NULL
N*-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
;	NULL
ELISA	NULL
,	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
;	NULL
ERK	NULL
,	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
;	NULL
HSA	NULL
,	NULL
human	NULL
serum	NULL
albumin	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
JNK	NULL
,	NULL
c-Jun	NULL
NH-terminal	NULL
kinase	NULL
;	NULL
MAPK	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
;	NULL
MCP	NULL
,	NULL
monocyte	NULL
chemoattractant	NULL
protein	NULL
;	NULL
NAC	NULL
,	NULL
N-acetyl-i-cysteine	NULL
;	NULL
NF	NULL
,	NULL
nuclear	NULL
factor	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
;	NULL
PTK	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
;	NULL
RAGE	NULL
,	NULL
receptor	NULL
for	NULL
AGE	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcriptase	NULL
;	NULL
SFM	NULL
,	NULL
serum-free	NULL
medium	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
lucose	NULL
and	NULL
other	NULL
reducing	NULL
sugars	NULL
can	NULL
react	NULL
nonenzymatically	NULL
with	NULL
amino	NULL
groups	NULL
of	NULL
pro	NULL
teins	NULL
and	NULL
lipids	NULL
to	NULL
form	NULL
Schiff	NULL
bases	NULL
that	NULL
,	NULL
through	NULL
multiple	NULL
rearrangements	NULL
,	NULL
are	NULL
transformed	NULL
into	NULL
irreversibly	NULL
cross-linked	NULL
fluorescent	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
(	NULL
AGEs	NULL
)	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

The	NULL
formation	NULL
and	NULL
accumulation	NULL
of	NULL
AGE	NULL
adducts	NULL
in	NULL
various	NULL
tissues	NULL
are	NULL
known	NULL
to	NULL
progress	NULL
as	NULL
a	NULL
function	NULL
of	NULL
age	NULL
and	NULL
glycemia	NULL
,	NULL
are	NULL
associated	NULL
with	NULL
altered	NULL
protein	NULL
structure	NULL
and	NULL
function	NULL
,	NULL
and	NULL
are	NULL
able	NULL
to	NULL
generate	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
and	NULL
induce	NULL
cellular	NULL
activation	NULL
and	NULL
inflammation	NULL
(	NULL
1,4	NULL
)	NULL
.	NULL

Accumulation	NULL
of	NULL
AGEs	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
numerous	NULL
diverse	NULL
disorders	NULL
,	NULL
including	NULL
diabetes	NULL
(	NULL
1,5	NULL
)	NULL
,	NULL
Alzheimer	NULL
's	NULL
disease	NULL
(	NULL
6,7	NULL
)	NULL
,	NULL
and	NULL
hemodialysis-associated	NULL
amyloidosis	NULL
(	NULL
8	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
natural	NULL
aging	NULL
process	NULL
(	NULL
1,9	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
pharmacological	NULL
inhibition	NULL
of	NULL
AGE	NULL
formation	NULL
prevents	NULL
vascular	NULL
complications	NULL
affecting	NULL
retina	NULL
,	NULL
kidney	NULL
,	NULL
and	NULL
nerves	NULL
in	NULL
long-term	NULL
diabetic	NULL
animals	NULL
provides	NULL
support	NULL
for	NULL
this	NULL
suggestion	NULL
(	NULL
1,10,11	NULL
)	NULL
.	NULL

One	NULL
mechanism	NULL
by	NULL
which	NULL
AGEs	NULL
exert	NULL
their	NULL
effects	NULL
on	NULL
cellular	NULL
function	NULL
is	NULL
via	NULL
interaction	NULL
with	NULL
specific	NULL
receptors	NULL
.	NULL

Several	NULL
AGE-binding	NULL
proteins	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
including	NULL
lactoferrin	NULL
(	NULL
12	NULL
)	NULL
,	NULL
oligosaccharyl	NULL
transferase	NULL
complex	NULL
protein	NULL
48	NULL
(	NULL
AGE-R1	NULL
)	NULL
(	NULL
13,14	NULL
)	NULL
,	NULL
80OK-H	NULL
protein	NULL
(	NULL
AGE-R2	NULL
)	NULL
(	NULL
13,14	NULL
)	NULL
,	NULL
galectin-3	NULL
(	NULL
AGE-R3	NULL
)	NULL
(	NULL
15	NULL
)	NULL
,	NULL
lysozyme	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
the	NULL
receptor	NULL
for	NULL
AGE	NULL
(	NULL
RAGE	NULL
)	NULL
(	NULL
12,17	NULL
)	NULL
.	NULL

RAGE	NULL
is	NULL
a	NULL
multiligand	NULL
member	NULL
of	NULL
the	NULL
immunoglobulin	NULL
superfamily	NULL
and	NULL
is	NULL
expressed	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
endothelial	NULL
cells	NULL
,	NULL
smooth	NULL
muscle	NULL
cells	NULL
,	NULL
lymphocytes	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
neurons	NULL
(	NULL
18,19	NULL
)	NULL
.	NULL

Increased	NULL
RAGE	NULL
expression	NULL
has	NULL
been	NULL
shown	NULL
in	NULL
both	NULL
endothelium	NULL
and	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
from	NULL
diabetic	NULL
patients	NULL
(	NULL
5,20	NULL
)	NULL
and	NULL
in	NULL
macrophages	NULL
from	NULL
patients	NULL
with	NULL
renal	NULL
failure	NULL
and	NULL
dialysis-related	NULL
amyloidosis	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Areas	NULL
of	NULL
enhanced	NULL
RAGE	NULL
immunoreactivity	NULL
colocalize	NULL
with	NULL
immunostaining	NULL
for	NULL
AGE-reactive	NULL
epitopes	NULL
.	NULL

Recent	NULL
studies	NULL
also	NULL
have	NULL
demonstrated	NULL
elevated	NULL
RAGE	NULL
expression	NULL
in	NULL
affected	NULL
neurons	NULL
in	NULL
Alzheimer	NULL
's	NULL
disease	NULL
(	NULL
7	NULL
)	NULL
and	NULL
in	NULL
vasculatures	NULL
affected	NULL
by	NULL
autoimmune/inflammatory	NULL
disorders	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Interruption	NULL
of	NULL
AGE-RAGE	NULL
interaction	NULL
by	NULL
administration	NULL
of	NULL
the	NULL
soluble	NULL
extracellular	NULL
domain	NULL
of	NULL
RAGE	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
suppress	NULL
diabetes-induced	NULL
vascular	NULL
hyperpermeability	NULL
(	NULL
22	NULL
)	NULL
and	NULL
the	NULL
accelerated	NULL
development	NULL
of	NULL
atherosclerosis	NULL
in	NULL
diabetic	NULL
apo-lipoprotein	NULL
E	NULL
knockout	NULL
mice	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Although	NULL
these	NULL
findings	NULL
support	NULL
a	NULL
causal	NULL
role	NULL
for	NULL
RAGE	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
1495	NULL
RAGE-MEDIATED	NULL
p38	NULL
MAPK-DEPENDENT	NULL
NF-B	NULL
ACTIVATION	NULL
diabetes-induced	NULL
vascular	NULL
functional	NULL
and	NULL
structural	NULL
changes	NULL
,	NULL
the	NULL
intracellular	NULL
mechanisms	NULL
by	NULL
which	NULL
AGE-RAGE	NULL
interaction	NULL
causes	NULL
vascular	NULL
dysfunction	NULL
remain	NULL
unclear	NULL
.	NULL

Interaction	NULL
of	NULL
AGE	NULL
with	NULL
RAGE	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
generate	NULL
an	NULL
oxidative	NULL
stress	NULL
that	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-kB	NULL
,	NULL
the	NULL
oxidant-sensitive	NULL
transcription	NULL
factor	NULL
(	NULL
24	NULL
)	NULL
.	NULL

NF-kB	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
development	NULL
of	NULL
a	NULL
proinflammatory	NULL
state	NULL
by	NULL
stimulating	NULL
expression	NULL
of	NULL
target	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
heme	NULL
oxygenase	NULL
(	NULL
25	NULL
)	NULL
,	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
VCAM-1	NULL
)	NULL
(	NULL
26	NULL
)	NULL
,	NULL
procoagulant	NULL
tissue	NULL
factor	NULL
(	NULL
27	NULL
)	NULL
,	NULL
endothelin-1	NULL
(	NULL
28	NULL
)	NULL
,	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
24	NULL
)	NULL
,	NULL
and	NULL
RAGE	NULL
itself	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Despite	NULL
these	NULL
observations	NULL
,	NULL
information	NULL
regarding	NULL
signal	NULL
transduction	NULL
from	NULL
RAGE	NULL
to	NULL
NF-	NULL
«	NULL
kB-induced	NULL
cytokine	NULL
secretion	NULL
remains	NULL
largely	NULL
unknown	NULL
.	NULL

Several	NULL
reports	NULL
have	NULL
linked	NULL
reactive	NULL
oxygen	NULL
species	NULL
(	NULL
24	NULL
)	NULL
,	NULL
p21	NULL
Ras	NULL
,	NULL
and	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
1	NULL
and	NULL
2	NULL
(	NULL
30	NULL
)	NULL
to	NULL
this	NULL
signaling	NULL
pathway	NULL
,	NULL
yet	NULL
the	NULL
potential	NULL
role	NULL
of	NULL
other	NULL
relevant	NULL
signaling	NULL
molecules	NULL
remains	NULL
unknown	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
elucidate	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
linked	NULL
to	NULL
RAGE	NULL
activation	NULL
in	NULL
monocytes	NULL
using	NULL
the	NULL
ligand	NULL
N°-	NULL
(	NULL
carboxymethylysine	NULL
(	NULL
CML	NULL
)	NULL
-modified	NULL
human	NULL
serum	NULL
albumin	NULL
(	NULL
HSA	NULL
)	NULL
.	NULL

CML	NULL
is	NULL
a	NULL
major	NULL
adduct	NULL
of	NULL
AGE-modified	NULL
proteins	NULL
that	NULL
accumulates	NULL
in	NULL
diabetic	NULL
patients	NULL
,	NULL
has	NULL
been	NULL
recognized	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
oxidative	NULL
stress	NULL
(	NULL
31,32	NULL
)	NULL
,	NULL
and	NULL
recently	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
a	NULL
ligand	NULL
for	NULL
RAGE	NULL
(	NULL
33	NULL
)	NULL
.	NULL

We	NULL
identified	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
as	NULL
a	NULL
key	NULL
downstream	NULL
effector	NULL
of	NULL
RAGE	NULL
,	NULL
since	NULL
p38	NULL
is	NULL
required	NULL
for	NULL
CML-HSA-induced	NULL
NF-kB	NULL
transcriptional	NULL
activation	NULL
and	NULL
the	NULL
subsequent	NULL
increased	NULL
secretion	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-a	NULL
,	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-16B	NULL
,	NULL
and	NULL
monocyte	NULL
chemoattractant	NULL
protein	NULL
(	NULL
MCP	NULL
)	NULL
-1	NULL
.	NULL

This	NULL
report	NULL
establishes	NULL
a	NULL
RAGE-p38	NULL
MAPK	NULL
-NF-kB-cytokine	NULL
signaling	NULL
cascade	NULL
in	NULL
monocytes	NULL
and	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
it	NULL
may	NULL
have	NULL
physiological	NULL
importance	NULL
in	NULL
the	NULL
development	NULL
of	NULL
the	NULL
proinflammatory	NULL
milieu	NULL
associated	NULL
with	NULL
such	NULL
diverse	NULL
diseases	NULL
as	NULL
Alzheimer	NULL
's	NULL
,	NULL
atherosclerosis	NULL
,	NULL
and	NULL
diabetes	NULL
.	NULL

RESEARCH	NULL
DESIGN	NULL
AND	NULL
METHODS	NULL
Materials	NULL
.	NULL

All	NULL
tissue	NULL
culture	NULL
reagents	NULL
were	NULL
purchased	NULL
from	NULL
Life	NULL
Technologies	NULL
and	NULL
were	NULL
documented	NULL
to	NULL
be	NULL
free	NULL
of	NULL
endotoxins	NULL
.	NULL

HSA	NULL
(	NULL
Fraction	NULL
V	NULL
)	NULL
,	NULL
glyoxylic	NULL
acid	NULL
,	NULL
and	NULL
sodium	NULL
cyanoborohydride	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

N-acetyl-t-cysteine	NULL
(	NULL
NAC	NULL
)	NULL
,	NULL
genistein	NULL
,	NULL
PD98059	NULL
,	NULL
and	NULL
SB203580	NULL
were	NULL
from	NULL
Calbiochem	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Anti-phosphotyrosine	NULL
antibody	NULL
(	NULL
PY99	NULL
)	NULL
was	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Anti-ERK1/2	NULL
,	NULL
anti-phospho-ERK1/2	NULL
,	NULL
anti-p38	NULL
,	NULL
anti-phospho-p38	NULL
,	NULL
anti-c-Jun	NULL
NH	NULL
,	NULL
-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
,	NULL
anti-phospho-JNK	NULL
,	NULL
and	NULL
anti-phospho-ATF2	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
New	NULL
England	NULL
BioLabs	NULL
(	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Synthetic	NULL
peptides	NULL
were	NULL
prepared	NULL
by	NULL
Dr.	NULL
Kaijun	NULL
Ren	NULL
(	NULL
Chemistry	NULL
Department	NULL
,	NULL
Texas	NULL
Biotechnology	NULL
Corporation	NULL
)	NULL
and	NULL
were	NULL
>	NULL
95	NULL
%	NULL
pure	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
.	NULL

The	NULL
expression	NULL
plasmid	NULL
for	NULL
the	NULL
p38	NULL
kinase-dead	NULL
dominant-negative	NULL
mutant	NULL
was	NULL
provided	NULL
by	NULL
Dr.	NULL
Roger	NULL
Davis	NULL
from	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Massachusetts	NULL
Medical	NULL
Center	NULL
(	NULL
Worcester	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
IxB	NULL
mutant	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
Chung	NULL
Y.	NULL
Hsu	NULL
at	NULL
Washington	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Both	NULL
mutants	NULL
are	NULL
in	NULL
the	NULL
peDNA3.1	NULL
expression	NULL
vector	NULL
.	NULL

Enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
kits	NULL
for	NULL
TNF-	NULL
«	NULL
,	NULL
IL-1B	NULL
,	NULL
and	NULL
MCP-1	NULL
were	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
CML-HSA	NULL
.	NULL

CML-HSA	NULL
was	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
175	NULL
mg/ml	NULL
HSA	NULL
was	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
24	NULL
h	NULL
in	NULL
0.2	NULL
mol/l	NULL
sodium	NULL
phosphate	NULL
buffer	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
containing	NULL
150	NULL
mmol/l	NULL
glyoxylic	NULL
acid	NULL
and	NULL
450	NULL
mmol/l	NULL
sodium	NULL
cyanoborohydride	NULL
,	NULL
followed	NULL
by	NULL
extensive	NULL
dialysis	NULL
against	NULL
2	NULL
L	NULL
phos-pate-buffered	NULL
saline	NULL
at	NULL
4°C	NULL
changed	NULL
twice	NULL
at	NULL
24h	NULL
intervals	NULL
.	NULL

The	NULL
resulting	NULL
CML-HSA	NULL
preparation	NULL
contained	NULL
~30	NULL
%	NULL
CML-modified	NULL
lysine	NULL
residues	NULL
per	NULL
molecule	NULL
albumin	NULL
based	NULL
on	NULL
amino	NULL
acid	NULL
analysis	NULL
.	NULL

Both	NULL
the	NULL
CML-HSA	NULL
and	NULL
the	NULL
control	NULL
HSA	NULL
were	NULL
documented	NULL
to	NULL
be	NULL
endotoxin-free	NULL
by	NULL
use	NULL
of	NULL
the	NULL
Limulus	NULL
amebocyte	NULL
lysate	NULL
assay	NULL
(	NULL
Sigma	NULL
E-TOXATE	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
limits	NULL
of	NULL
detection	NULL
were	NULL
0.015	NULL
EU/m	NULL
!	NULL

(	NULL
turbid	NULL
gel	NULL
)	NULL
,	NULL
0.03	NULL
EU/m	NULL
!	NULL

(	NULL
soft	NULL
gel	NULL
)	NULL
,	NULL
and	NULL
0.06	NULL
EU/m	NULL
!	NULL

(	NULL
hard	NULL
gel	NULL
)	NULL
.	NULL

1496	NULL
Cell	NULL
culture	NULL
.	NULL

Human	NULL
THP-1	NULL
monocytic	NULL
leukemia	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
ATCC	NULL
TIB-202	NULL
;	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
50	NULL
mol/l	NULL
2-mercaptoethanol	NULL
,	NULL
2	NULL
mmol/l	NULL
glutamine	NULL
,	NULL
100	NULL
U	NULL
penicillin	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
atmosphere	NULL
.	NULL

Log-phase	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
all	NULL
experiments	NULL
.	NULL

Human	NULL
peripheral	NULL
monocytes	NULL
were	NULL
isolated	NULL
from	NULL
healthy	NULL
donors	NULL
'	NULL
blood	NULL
(	NULL
SeraCare	NULL
,	NULL
Oceanside	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
standard	NULL
Ficoll-Hypaque	NULL
(	NULL
Amersham	NULL
Phar-macia	NULL
Biotech	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
density-gradient	NULL
centrifugation	NULL
followed	NULL
by	NULL
adherence	NULL
depletion	NULL
of	NULL
lymphocytes	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
85	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
seeded	NULL
at	NULL
4	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
a	NULL
48-well	NULL
plate	NULL
and	NULL
treated	NULL
with	NULL
100	NULL
pg/ml	NULL
HSA	NULL
or	NULL
CML-HSA	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
SB203580	NULL
or	NULL
PD98059	NULL
for	NULL
24	NULL
h	NULL
before	NULL
measurement	NULL
of	NULL
TNF-	NULL
«	NULL
in	NULL
the	NULL
culture	NULL
media	NULL
by	NULL
ELISA	NULL
.	NULL

Anti-RAGE	NULL
antiserum	NULL
preparation	NULL
.	NULL

The	NULL
human	NULL
RAGE	NULL
extracellular	NULL
domain	NULL
encompassing	NULL
residues	NULL
23-340	NULL
(	NULL
sRAGE	NULL
)	NULL
was	NULL
expressed	NULL
and	NULL
purified	NULL
from	NULL
Escherichia	NULL
coli	NULL
using	NULL
the	NULL
pET	NULL
thioredoxin	NULL
system	NULL
(	NULL
Novagen	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

For	NULL
antiserum	NULL
production	NULL
,	NULL
BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
100	NULL
ug	NULL
sRAGE	NULL
protein	NULL
in	NULL
complete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
,	NULL
and	NULL
an	NULL
additional	NULL
50	NULL
ug	NULL
sRAGE	NULL
in	NULL
incomplete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
was	NULL
given	NULL
every	NULL
4	NULL
weeks	NULL
until	NULL
a	NULL
high	NULL
serum	NULL
titer	NULL
was	NULL
achieved	NULL
.	NULL

NF-kB	NULL
reporter	NULL
neutralizing	NULL
activity	NULL
of	NULL
the	NULL
antiserum	NULL
was	NULL
measured	NULL
by	NULL
preincubation	NULL
with	NULL
THP-1	NULL
cells	NULL
(	NULL
1:5	NULL
or	NULL
1:25	NULL
dilution	NULL
of	NULL
the	NULL
antiserum	NULL
)	NULL
for	NULL
1	NULL
h	NULL
before	NULL
exposure	NULL
to	NULL
CML-HSA	NULL
.	NULL

DEAE/dextran-mediated	NULL
cell	NULL
transfection	NULL
and	NULL
luciferase	NULL
assay	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
100-mm	NULL
dish	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
serum-free	NULL
medium	NULL
(	NULL
SFM	NULL
)	NULL
the	NULL
day	NULL
before	NULL
transfection	NULL
.	NULL

Transfection	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
36	NULL
)	NULL
,	NULL
with	NULL
minor	NULL
modifications	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
SFM	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
containing	NULL
2	NULL
pg	NULL
NF-	NULL
«	NULL
B-Luc	NULL
reporter	NULL
plasmid	NULL
(	NULL
Clontech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
200	NULL
ug/ml	NULL
DEAE-dextran	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WID	NULL
)	NULL
.	NULL

The	NULL
cell-DNA	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20-30	NULL
min	NULL
before	NULL
washing	NULL
,	NULL
centrifugation	NULL
,	NULL
and	NULL
resuspension	NULL
into	NULL
fresh	NULL
SFM	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
seeded	NULL
into	NULL
96-well	NULL
plates	NULL
at	NULL
70,000	NULL
cells	NULL
per	NULL
well	NULL
for	NULL
recovery	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
control	NULL
albumin	NULL
or	NULL
CML-modified	NULL
albumin	NULL
for	NULL
10	NULL
min	NULL
to	NULL
24	NULL
h	NULL
before	NULL
cell	NULL
harvest	NULL
.	NULL

Equivalent	NULL
amounts	NULL
of	NULL
cell	NULL
lysates	NULL
,	NULL
normalized	NULL
for	NULL
total	NULL
protein	NULL
(	NULL
Bradford	NULL
protein	NULL
assay	NULL
;	NULL
Bio-Rad	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
were	NULL
used	NULL
for	NULL
measurement	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
Steady-Glo	NULL
luciferase	NULL
assay	NULL
system	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
luminescence	NULL
was	NULL
detected	NULL
in	NULL
a	NULL
TopCount	NULL
microplate	NULL
scintillation	NULL
counter	NULL
,	NULL
using	NULL
a	NULL
single-photon	NULL
monitor	NULL
program	NULL
(	NULL
Packard	NULL
Instrument	NULL
Company	NULL
,	NULL
Meriden	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

For	NULL
cotransfection	NULL
experiments	NULL
,	NULL
10	NULL
ug	NULL
(	NULL
10-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
expression	NULL
plasmid	NULL
was	NULL
used	NULL
with	NULL
1	NULL
g	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
,	NULL
with	NULL
the	NULL
empty	NULL
vector	NULL
serving	NULL
as	NULL
a	NULL
transfection	NULL
control	NULL
.	NULL

Transfection	NULL
efficiency	NULL
in	NULL
THP-1	NULL
cells	NULL
was	NULL
20-30	NULL
%	NULL
,	NULL
as	NULL
monitored	NULL
by	NULL
cotransfection	NULL
with	NULL
a	NULL
-galactosidase	NULL
expression	NULL
plasmid	NULL
(	NULL
Clontech	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
using	NULL
the	NULL
protocol	NULL
of	NULL
Schreiber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
87	NULL
)	NULL
,	NULL
with	NULL
minor	NULL
modifications	NULL
.	NULL

Briefly	NULL
,	NULL
2-4	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
,	NULL
then	NULL
resuspended	NULL
by	NULL
gentle	NULL
pipetting	NULL
in	NULL
400	NULL
pl	NULL
cold	NULL
buffer	NULL
containing	NULL
10	NULL
mmol/l	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
mmol	NULL
KCI	NULL
,	NULL
0.1	NULL
mmol/l	NULL
EDTA	NULL
,	NULL
0.1	NULL
mmol	NULL
EGTA	NULL
,	NULL
1	NULL
mmol/l	NULL
.	NULL

dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
and	NULL
0.5	NULL
mmol	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
suspension	NULL
was	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
,	NULL
after	NULL
which	NULL
Nonidet-P40	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
%	NULL
.	NULL

The	NULL
homogenate	NULL
was	NULL
subjected	NULL
to	NULL
centrifugation	NULL
for	NULL
10	NULL
s	NULL
;	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
50	NULL
ul	NULL
ice-cold	NULL
buffer	NULL
containing	NULL
20	NULL
mmol/	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
0.4	NULL
mol/l	NULL
NaCl	NULL
,	NULL
1	NULL
mmol/	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/	NULL
EGTA	NULL
,	NULL
1	NULL
mmol/l	NULL
DTT	NULL
,	NULL
and	NULL
1	NULL
mmol/l	NULL
PMSF	NULL
;	NULL
and	NULL
the	NULL
tube	NULL
was	NULL
rocked	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
on	NULL
a	NULL
shaking	NULL
platform	NULL
then	NULL
dialyzed	NULL
against	NULL
reaction	NULL
buffer	NULL
(	NULL
20	NULL
mmol/l	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
50	NULL
mmol/l	NULL
KC	NULL
]	NULL
,	NULL
0.2	NULL
mmol/l	NULL
EDTA	NULL
,	NULL
1	NULL
mmol/l	NULL
MgC	NULL
]	NULL
,	NULL
,	NULL
and	NULL
1	NULL
mmol/l	NULL
DTT	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
was	NULL
spun	NULL
for	NULL
5	NULL
min	NULL
in	NULL
the	NULL
cold	NULL
room	NULL
.	NULL

Total	NULL
protein	NULL
content	NULL
of	NULL
the	NULL
supernatant	NULL
was	NULL
determined	NULL
,	NULL
with	NULL
the	NULL
remainder	NULL
stored	NULL
at	NULL
-70°C	NULL
in	NULL
aliquots	NULL
.	NULL

Some	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
was	NULL
mixed	NULL
with	NULL
2	NULL
pg	NULL
poly	NULL
dl-dC	NULL
and	NULL
~200	NULL
pg	NULL
(	NULL
10,000	NULL
cpm	NULL
)	NULL
of	NULL
radiolabeled	NULL
double-stranded	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
c-myc	NULL
NF-kB	NULL
binding	NULL
site	NULL
(	NULL
CGTTGGGAAAACCCGGGATT	NULL
)	NULL
in	NULL
reaction	NULL
buffer	NULL
to	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
30	NULL
ul	NULL
and	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
25	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
run	NULL
on	NULL
a	NULL
5	NULL
%	NULL
(	NULL
30:1	NULL
)	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
buffer	NULL
.	NULL

Radiolabeled	NULL
probes	NULL
were	NULL
prepared	NULL
by	NULL
labeling	NULL
one	NULL
of	NULL
the	NULL
oligonucleotides	NULL
comprising	NULL
the	NULL
DNA	NULL
binding	NULL
site	NULL
and	NULL
then	NULL
annealing	NULL
it	NULL
to	NULL
its	NULL
unlabeled	NULL
partner	NULL
.	NULL

Radiolabeling	NULL
was	NULL
performed	NULL
using	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
[	NULL
y-*P	NULL
]	NULL
JATP	NULL
.	NULL

After	NULL
this	NULL
reaction	NULL
,	NULL
unincorporated	NULL
nucleotides	NULL
and	NULL
the	NULL
T4	NULL
kinase	NULL
buffer	NULL
were	NULL
removed	NULL
,	NULL
the	NULL
unlabeled	NULL
oligonucleotide	NULL
was	NULL
added	NULL
,	NULL
and	NULL
it	NULL
was	NULL
heated	NULL
to	NULL
80°C	NULL
and	NULL
then	NULL
allowed	NULL
to	NULL
cool	NULL
slowly	NULL
to	NULL
room	NULL
temperature	NULL
.	NULL

RAGE-expression	NULL
plasmids	NULL
.	NULL

A	NULL
cDNA-encoding	NULL
RAGE	NULL
was	NULL
generated	NULL
by	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
-polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
using	NULL
human	NULL
lung	NULL
mRNA	NULL
as	NULL
a	NULL
source	NULL
for	NULL
the	NULL
cDNA	NULL
and	NULL
primers	NULL
based	NULL
on	NULL
the	NULL
published	NULL
full-length	NULL
sequence	NULL
(	NULL
GenBank	NULL
AFOQ1095	NULL
)	NULL
.	NULL

The	NULL
product	NULL
was	NULL
fully	NULL
sequenced	NULL
and	NULL
then	NULL
subcloned	NULL
into	NULL
the	NULL
eucaryotic	NULL
expression	NULL
vector	NULL
pcDNA8.1	NULL
(	NULL
*Jneo	NULL
.	NULL

DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
C.-H.	NULL
YEH	NULL
AND	NULL
ASSOCIATES	NULL
A	NULL
g	NULL
200	NULL
f	NULL
C	NULL
>	NULL
2	NULL
iso	NULL
*c	NULL
``	NULL
k	NULL
g	NULL
*	NULL
HSA	NULL
-|	NULL
_-	NULL
-	NULL
_-	NULL
=	NULL
§	NULL
'*	NULL
CML-HSA	NULL
-_-	NULL
f	NULL
<	NULL
-	NULL
3	NULL
TNFa	NULL
=	NULL
=	NULL
=~	NULL
=-	NULL
++	NULL
50	NULL
4	NULL
>	NULL
Competitor	NULL
=	NULL
=	NULL
=	NULL
#	NULL
$	NULL
-	NULL
#	NULL
3	NULL
C	NULL
0	NULL
+	NULL
0	NULL
50	NULL
100	NULL
200	NULL
300	NULL
CML	NULL
(	NULL
ug/ml	NULL
)	NULL
F	NULL
|	NULL
i	NULL
|	NULL
<	NULL
:	NULL
n	NULL
|	NULL
|	NULL
g	NULL
20	NULL
6	NULL
*	NULL
a	NULL
150	NULL
*	NULL
*	NULL
*	NULL
©	NULL
-	NULL
>	NULL
g	NULL
100	NULL
3	NULL
$	NULL
®	NULL
©	NULL
E	NULL
od	NULL
|	NULL
o	NULL
03	NULL
1	NULL
2	NULL
4	NULL
6	NULL
1	NULL
Exposure	NULL
time	NULL
(	NULL
h	NULL
)	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

CML-HSA	NULL
induces	NULL
NF-xB	NULL
transcriptional	NULL
activation	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

A	NULL
:	NULL
Concentration-dependent	NULL
stimulation	NULL
of	NULL
NF-	NULL
«	NULL
B-luciferase	NULL
reporter	NULL
by	NULL
CML-HSA	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B-Luc	NULL
reporter	NULL
gene	NULL
,	NULL
treated	NULL
1	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
CML-HSA	NULL
,	NULL
and	NULL
harvested	NULL
for	NULL
analysis	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

B	NULL
:	NULL
Time-dependent	NULL
stimulation	NULL
of	NULL
NF-	NULL
«	NULL
B-luciferase	NULL
reporter	NULL
by	NULL
CML-HSA	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
100	NULL
ug/ml	NULL
CML-HSA	NULL
for	NULL
the	NULL
indicated	NULL
period	NULL
of	NULL
time	NULL
followed	NULL
by	NULL
luciferase	NULL
measurement	NULL
.	NULL

Relative	NULL
luciferase	NULL
activities	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
SE	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
with	NULL
triplicate	NULL
determinations	NULL
,	NULL
setting	NULL
the	NULL
basal	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
no	NULL
CML-HSA	NULL
exposure	NULL
)	NULL
at	NULL
100	NULL
%	NULL
.	NULL

C	NULL
:	NULL
CML-HSA	NULL
treatment	NULL
resulted	NULL
in	NULL
increased	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Some	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
THP-1	NULL
cells	NULL
treated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
100	NULL
pg/ml	NULL
HSA	NULL
,	NULL
100	NULL
ug/ml	NULL
CML-HSA	NULL
,	NULL
or	NULL
10	NULL
ng/ml	NULL
recombinant	NULL
human	NULL
TNF-	NULL
«	NULL
was	NULL
incubated	NULL
with	NULL
radiolabeled	NULL
double-stranded	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
c-myc	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
excess	NULL
unlabeled	NULL
probe	NULL
(	NULL
competitor	NULL
)	NULL
.	NULL

The	NULL
single	NULL
arrow	NULL
indicates	NULL
nonspecific	NULL
binding	NULL
to	NULL
the	NULL
probe	NULL
,	NULL
and	NULL
the	NULL
double	NULL
arrows	NULL
indicate	NULL
specific	NULL
DNA	NULL
binding	NULL
that	NULL
is	NULL
effectively	NULL
competed	NULL
by	NULL
adding	NULL
excess	NULL
unlabeled	NULL
double-stranded	NULL
probe	NULL
or	NULL
is	NULL
absent	NULL
when	NULL
the	NULL
binding	NULL
site	NULL
was	NULL
altered	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
basal	NULL
levels	NULL
.	NULL

RAGE	NULL
lacking	NULL
its	NULL
intracellular	NULL
domain	NULL
was	NULL
constructed	NULL
by	NULL
PCR-based	NULL
site-directed	NULL
mutagenesis	NULL
using	NULL
primers	NULL
to	NULL
introduce	NULL
a	NULL
termination	NULL
codon	NULL
immediately	NULL
after	NULL
amino	NULL
acid	NULL
364	NULL
(	NULL
RAGE-365t	NULL
)	NULL
or	NULL
amino	NULL
acid	NULL
371	NULL
(	NULL
RAGE-372t	NULL
)	NULL
.	NULL

RAGE-365t	NULL
terminates	NULL
two	NULL
amino	NULL
acids	NULL
after	NULL
the	NULL
hydrophobic	NULL
region	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
transmembrane	NULL
domain	NULL
,	NULL
whereas	NULL
RAGE-372t	NULL
retains	NULL
only	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
cytosolic	NULL
tail	NULL
that	NULL
is	NULL
not	NULL
well	NULL
conserved	NULL
across	NULL
species	NULL
.	NULL

Western	NULL
blotting	NULL
analysis	NULL
.	NULL

THP-1	NULL
monocytes	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
solubilized	NULL
in	NULL
a	NULL
lysis	NULL
buffer	NULL
containing	NULL
50	NULL
mmol/l	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
150	NULL
mmol/l	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
Nonidet-P40	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
,	NULL
and	NULL
protease	NULL
inhibitor	NULL
cocktail	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Cellular	NULL
lysates	NULL
(	NULL
50	NULL
ug	NULL
)	NULL
were	NULL
fractionated	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
analyzed	NULL
by	NULL
immunoblotting	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
indicated	NULL
primary	NULL
antibodies	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
of	NULL
each	NULL
manufacturer	NULL
.	NULL

Blots	NULL
were	NULL
then	NULL
stained	NULL
with	NULL
the	NULL
corresponding	NULL
anti-rabbit	NULL
or	NULL
anti-mouse	NULL
IgG-horseradish-peroxidase	NULL
conjugate	NULL
(	NULL
1:3,000	NULL
dilution	NULL
)	NULL
and	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
reagent	NULL
(	NULL
ECL	NULL
,	NULL
;	NULL
Amer-sham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Autoradiography	NULL
was	NULL
done	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
the	NULL
appropriate	NULL
exposures	NULL
were	NULL
quantitated	NULL
by	NULL
densitometry	NULL
.	NULL

Measurement	NULL
of	NULL
cytokine	NULL
secretion	NULL
.	NULL

ELISA	NULL
was	NULL
used	NULL
for	NULL
quantitative	NULL
measurement	NULL
of	NULL
released	NULL
TNF-	NULL
«	NULL
,	NULL
I-18	NULL
,	NULL
and	NULL
MCP-1	NULL
.	NULL

After	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
the	NULL
media	NULL
was	NULL
collected	NULL
and	NULL
analyzed	NULL
by	NULL
ELISA	NULL
according	NULL
to	NULL
each	NULL
protocol	NULL
provided	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

Quantitative	NULL
data	NULL
were	NULL
expressed	NULL
as	NULL
means	NULL
+	NULL
SE	NULL
,	NULL
based	NULL
on	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

Unpaired	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
the	NULL
significance	NULL
of	NULL
differences	NULL
among	NULL
treatments	NULL
.	NULL

A	NULL
P	NULL
value	NULL
<	NULL
0.05	NULL
was	NULL
considered	NULL
significant	NULL
.	NULL

RESULTS	NULL
CML-HSA	NULL
activates	NULL
NF-KB	NULL
transcriptional	NULL
activity	NULL
in	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
.	NULL

AGEs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
stimulate	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
vitro	NULL
in	NULL
a	NULL
number	NULL
of	NULL
DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
cell	NULL
types	NULL
(	NULL
24,26,30,33	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
CML-HSA	NULL
induces	NULL
NF-	NULL
<	NULL
B	NULL
transcriptional	NULL
activity	NULL
,	NULL
we	NULL
used	NULL
the	NULL
THP-1	NULL
monocytic	NULL
cell	NULL
line	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
NF-kB	NULL
reporter	NULL
gene	NULL
.	NULL

Both	NULL
RT-PCR	NULL
and	NULL
Western	NULL
blot	NULL
were	NULL
used	NULL
to	NULL
demonstrate	NULL
the	NULL
presence	NULL
of	NULL
RAGE	NULL
mRNA	NULL
and	NULL
protein	NULL
,	NULL
respectively	NULL
,	NULL
within	NULL
THP-1	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Transfected	NULL
cells	NULL
incubated	NULL
with	NULL
native	NULL
HSA	NULL
or	NULL
without	NULL
CMLHSA	NULL
treatment	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
basal	NULL
luciferase	NULL
activity	NULL
.	NULL

Treatment	NULL
with	NULL
CML-HSA	NULL
at	NULL
>	NULL
100	NULL
pg/ml	NULL
stimulated	NULL
reporter	NULL
gene	NULL
expression	NULL
by	NULL
~1.7-fold	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
basal	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

CML-HSA	NULL
exposure	NULL
initiated	NULL
a	NULL
fast	NULL
and	NULL
statistically	NULL
significant	NULL
NF-kB	NULL
response	NULL
,	NULL
with	NULL
an	NULL
initial	NULL
induction	NULL
observed	NULL
as	NULL
early	NULL
as	NULL
20	NULL
min	NULL
after	NULL
treatment	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
elevated	NULL
approximately	NULL
twofold	NULL
within	NULL
the	NULL
first	NULL
hour	NULL
and	NULL
remained	NULL
essentially	NULL
unchanged	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
further	NULL
luciferase	NULL
accumulation	NULL
after	NULL
1	NULL
h	NULL
suggests	NULL
an	NULL
acute	NULL
activation	NULL
and	NULL
deactivation	NULL
of	NULL
NF-	NULL
«	NULL
kB	NULL
,	NULL
whereas	NULL
the	NULL
prolonged	NULL
signal	NULL
probably	NULL
reflects	NULL
the	NULL
stability	NULL
of	NULL
the	NULL
luciferase	NULL
protein	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
10	NULL
,	NULL
5	NULL
,	NULL
and	NULL
1	NULL
%	NULL
CML	NULL
modification	NULL
of	NULL
HSA	NULL
was	NULL
tested	NULL
using	NULL
the	NULL
NF-kB	NULL
reporter	NULL
assay	NULL
,	NULL
and	NULL
a	NULL
similar	NULL
1.5-	NULL
to	NULL
1.7-fold	NULL
increase	NULL
in	NULL
the	NULL
luciferase	NULL
signal	NULL
was	NULL
observed	NULL
at	NULL
modifications	NULL
of	NULL
>	NULL
5	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
THP	NULL
cells	NULL
treated	NULL
with	NULL
either	NULL
TNF-	NULL
«	NULL
or	NULL
CML-HSA	NULL
showed	NULL
a	NULL
large	NULL
increase	NULL
in	NULL
specific	NULL
1497	NULL
RAGE-MEDIATED	NULL
p38	NULL
MAPK-DEPENDENT	NULL
NF-B	NULL
ACTIVATION	NULL
A	NULL
B	NULL
€	NULL
T	NULL
20	NULL
2	NULL
~	NULL
5	NULL
i	NULL
F7	NULL
%	NULL
ti	NULL
200	NULL
T	NULL
g	NULL
150	NULL
C	NULL
*	NULL
8	NULL
so	NULL
g	NULL
100	NULL
g	NULL
*	NULL
*	NULL
£	NULL
*	NULL
T	NULL
100	NULL
I	NULL
I	NULL
S	NULL
2	NULL
8	NULL
so	NULL
Z	NULL
-so	NULL
a	NULL
€	NULL
G	NULL
S	NULL
&	NULL
C	NULL
-	NULL
o	NULL
4	NULL
m	NULL
o	NULL
08	NULL
-	NULL
-	NULL
.	NULL

C	NULL
CML	NULL
-o	NULL
#	NULL
+0	NULL
+0	NULL
+0	NULL
+	NULL
+	NULL
RAGE	NULL
:	NULL
WT	NULL
37	NULL
2t	NULL
365t	NULL
Peptide	NULL
:	NULL
0.2	NULL
x	NULL
20	NULL
x	NULL
Neutralizing	NULL
+	NULL
+	NULL
antiserum	NULL
:	NULL
(	NULL
1:5	NULL
)	NULL
(	NULL
1:25	NULL
)	NULL
C	NULL
ontrol	NULL
4	NULL
antiserum	NULL
:	NULL
C	NULL
peDNA3.1-RAGE	NULL
peDNA3.1	NULL
WT	NULL
365t	NULL
HSA	NULL
.L	NULL
.	NULL

L	NULL
o	NULL
_L	NULL
kos	NULL
s	NULL
$	NULL
s	NULL
_.	NULL
poe	NULL
CML-HSA	NULL
L	NULL
=_	NULL
-	NULL
op	NULL
$	NULL
o	NULL
-	NULL
&	NULL
-	NULL
$	NULL
o	NULL
~	NULL
TNF-C	NULL
.	NULL

op	NULL
fe	NULL
e	NULL
ons	NULL
Ome	NULL
ome	NULL
(	NULL
inl	NULL
Cn	NULL
)	NULL
(	NULL
mel	NULL
me	NULL
Compel	NULL
.	NULL

z	NULL
4	NULL
z	NULL
o	NULL
$	NULL
-	NULL
-	NULL
-	NULL
=	NULL
=	NULL
)	NULL
®	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Requirement	NULL
for	NULL
RAGE	NULL
in	NULL
the	NULL
CML-HSA-induced	NULL
NF-	NULL
«	NULL
B	NULL
response	NULL
.	NULL

Blockade	NULL
of	NULL
CML-HSA-mediated	NULL
NF-xB	NULL
transcriptional	NULL
activation	NULL
by	NULL
a	NULL
synthetic	NULL
peptide	NULL
and	NULL
neutralizing	NULL
antiserum	NULL
(	NULL
A	NULL
)	NULL
or	NULL
by	NULL
coexpression	NULL
of	NULL
RAGE	NULL
truncation	NULL
mutants	NULL
(	NULL
B	NULL
)	NULL
.	NULL

A	NULL
:	NULL
100	NULL
ug/ml	NULL
CML-HSA	NULL
was	NULL
preincubated	NULL
with	NULL
or	NULL
without	NULL
a	NULL
synthetic	NULL
peptide	NULL
derived	NULL
from	NULL
the	NULL
extracellular	NULL
ligand-binding	NULL
domain	NULL
of	NULL
RAGE	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
mixtures	NULL
were	NULL
then	NULL
added	NULL
to	NULL
cell	NULL
cultures	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
1	NULL
h	NULL
before	NULL
analysis	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

For	NULL
the	NULL
neutralizing	NULL
antiserum	NULL
experiments	NULL
,	NULL
RAGE	NULL
antiserum	NULL
(	NULL
at	NULL
1:5	NULL
and	NULL
1:25	NULL
dilution	NULL
)	NULL
or	NULL
the	NULL
preimmune	NULL
control	NULL
serum	NULL
(	NULL
1:5	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
the	NULL
transfected	NULL
cells	NULL
for	NULL
1	NULL
h	NULL
before	NULL
CML-HSA	NULL
stimulation	NULL
.	NULL

Results	NULL
from	NULL
native	NULL
HSA	NULL
treatment	NULL
were	NULL
set	NULL
at	NULL
100	NULL
%	NULL
.	NULL

B	NULL
:	NULL
Full-length	NULL
(	NULL
wild-type	NULL
)	NULL
RAGE	NULL
or	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
truncation	NULL
mutants	NULL
RAGE-372t	NULL
or	NULL
RAGE-365t	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
into	NULL
THP-1	NULL
cells	NULL
.	NULL

After	NULL
24	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
100	NULL
ug/ml	NULL
CML-HSA	NULL
or	NULL
HSA	NULL
for	NULL
1	NULL
h	NULL
before	NULL
determinaton	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

Results	NULL
shown	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
HSA	NULL
control	NULL
.	NULL

C	NULL
:	NULL
Cells	NULL
transfected	NULL
with	NULL
empty	NULL
vector	NULL
,	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
,	NULL
or	NULL
mutant	NULL
(	NULL
365t	NULL
)	NULL
RAGE	NULL
and	NULL
treated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
100	NULL
ug/ml	NULL
HSA	NULL
,	NULL
100	NULL
pg/ml	NULL
CML-HSA	NULL
,	NULL
or	NULL
10	NULL
ng/ml	NULL
recombinant	NULL
human	NULL
TNF-a	NULL
.	NULL

We	NULL
incubated	NULL
5	NULL
ug	NULL
nuclear	NULL
extract	NULL
with	NULL
radiolabeled	NULL
double-stranded	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
c-myc	NULL
NF-B	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
excess	NULL
unlabeled	NULL
probe	NULL
(	NULL
competitor	NULL
)	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
means	NULL
+	NULL
SE	NULL
of	NULL
triplicate	NULL
determinations	NULL
in	NULL
three	NULL
separate	NULL
experiments	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

binding	NULL
to	NULL
the	NULL
radiolabeled	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
DNA	NULL
binding	NULL
(	NULL
single	NULL
arrow	NULL
)	NULL
.	NULL

Unmodified	NULL
HSA	NULL
treatment	NULL
c-myc	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Specificity	NULL
was	NULL
con-	NULL
-	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
DNA	NULL
binding	NULL
over	NULL
that	NULL
observed	NULL
in	NULL
un-firmed	NULL
by	NULL
demonstrating	NULL
that	NULL
inclusion	NULL
of	NULL
10-fold	NULL
molar	NULL
treated	NULL
extracts	NULL
.	NULL

excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
probe	NULL
prevented	NULL
the	NULL
ap-	NULL
CML-HSA-mediated	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activa-pearance	NULL
of	NULL
specific	NULL
(	NULL
double	NULL
arrows	NULL
)	NULL
,	NULL
but	NULL
not	NULL
nonspecific	NULL
,	NULL
tion	NULL
requires	NULL
RAGE	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
role	NULL
of	NULL
RAGE	NULL
in	NULL
1498	NULL
DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
C.-H.	NULL
YEH	NULL
AND	NULL
ASSOCIATES	NULL
200	NULL
-	NULL
_	NULL
]	NULL
150	NULL
{	NULL
100	NULL
-	NULL
*	NULL
*	NULL
50	NULL
;	NULL
Relative	NULL
luciferase	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
N-acetyl-L-cysteine	NULL
,	NULL
genistein	NULL
,	NULL
PD98059	NULL
,	NULL
and	NULL
S	NULL
$	NULL
B203580	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
stimulation	NULL
by	NULL
CML-HSA	NULL
.	NULL

THP-1	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
NF-	NULL
<	NULL
B	NULL
reporter	NULL
were	NULL
preincubated	NULL
with	NULL
the	NULL
antioxidant	NULL
N-acetyl-L-cysteine	NULL
(	NULL
NAC	NULL
,	NULL
500	NULL
pmol/l	NULL
)	NULL
,	NULL
a	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
genistein	NULL
(	NULL
100	NULL
mol/l	NULL
)	NULL
,	NULL
an	NULL
MEK-1	NULL
inhibitor	NULL
(	NULL
PD98059	NULL
,	NULL
50	NULL
umol/l	NULL
)	NULL
,	NULL
or	NULL
a	NULL
p38	NULL
inhibitor	NULL
(	NULL
SB203580	NULL
,	NULL
10	NULL
mol/l	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
exposed	NULL
to	NULL
100	NULL
ug/ml	NULL
CML-HSA	NULL
for	NULL
another	NULL
1	NULL
h	NULL
and	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
reporter	NULL
activity	NULL
with	NULL
HSA	NULL
treatment	NULL
was	NULL
defined	NULL
as	NULL
100	NULL
%	NULL
.	NULL

All	NULL
values	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
SE	NULL
of	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

CML-HSA-mediated	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
,	NULL
we	NULL
prepared	NULL
synthetic	NULL
peptides	NULL
based	NULL
on	NULL
sequences	NULL
derived	NULL
from	NULL
the	NULL
RAGE	NULL
extracellular	NULL
domain	NULL
that	NULL
have	NULL
high	NULL
probability	NULL
of	NULL
solvent	NULL
accessibility	NULL
.	NULL

A	NULL
17-amino	NULL
acid	NULL
peptide	NULL
encompassing	NULL
residues	NULL
102-118	NULL
of	NULL
RAGE	NULL
neutralized	NULL
CML-HSA	NULL
activity	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
such	NULL
that	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
effectively	NULL
eliminated	NULL
the	NULL
NF-kB	NULL
response	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Peptides	NULL
corresponding	NULL
to	NULL
amino	NULL
acids	NULL
39-56	NULL
and	NULL
amino	NULL
acids	NULL
67-82	NULL
(	NULL
both	NULL
predicted	NULL
to	NULL
have	NULL
a	NULL
high	NULL
probability	NULL
of	NULL
solvent	NULL
accessibility	NULL
)	NULL
had	NULL
no	NULL
detectable	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mouse	NULL
antiserum	NULL
to	NULL
sRAGE	NULL
also	NULL
blocked	NULL
the	NULL
CML-HSA-induced	NULL
NF-	NULL
«	NULL
B	NULL
response	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

To	NULL
more	NULL
clearly	NULL
define	NULL
the	NULL
role	NULL
of	NULL
RAGE	NULL
in	NULL
CML-HSA	NULL
signaling	NULL
to	NULL
NF-kB	NULL
,	NULL
we	NULL
generated	NULL
two	NULL
RAGE	NULL
cytoplasmic	NULL
domain	NULL
truncation	NULL
mutants	NULL
:	NULL
RAGE-365t	NULL
lacks	NULL
the	NULL
whole	NULL
intracellular	NULL
domain	NULL
,	NULL
whereas	NULL
RAGE-372t	NULL
retains	NULL
a	NULL
small	NULL
nonconserved	NULL
portion	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

Both	NULL
mutants	NULL
and	NULL
wild-type	NULL
RAGE	NULL
were	NULL
individually	NULL
coexpressed	NULL
with	NULL
the	NULL
NF-kB	NULL
reporter	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
full-length	NULL
(	NULL
wild-type	NULL
)	NULL
RAGE	NULL
,	NULL
the	NULL
mutants	NULL
blocked	NULL
the	NULL
NF-	NULL
<	NULL
B	NULL
response	NULL
to	NULL
CML-HSA	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
when	NULL
changes	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
were	NULL
measured	NULL
by	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
an	NULL
empty	NULL
vector	NULL
(	NULL
peDNA3.1	NULL
)	NULL
,	NULL
wild-type	NULL
RAGE	NULL
,	NULL
or	NULL
the	NULL
RAGE-365t	NULL
.	NULL

Both	NULL
control	NULL
and	NULL
wild-type	NULL
RAGE-transfected	NULL
cells	NULL
showed	NULL
no	NULL
increase	NULL
in	NULL
basal	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
but	NULL
exhibited	NULL
a	NULL
large	NULL
increase	NULL
after	NULL
incubation	NULL
with	NULL
CML-HSA	NULL
.	NULL

RAGE-365t	NULL
decreased	NULL
the	NULL
response	NULL
to	NULL
CML-HSA	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
intracellular	NULL
domain	NULL
of	NULL
RAGE	NULL
is	NULL
required	NULL
for	NULL
CML-HSA-induced	NULL
signaling	NULL
to	NULL
NF-kB	NULL
and	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
RAGE	NULL
in	NULL
which	NULL
this	NULL
domain	NULL
has	NULL
been	NULL
removed	NULL
acts	NULL
to	NULL
block	NULL
endogenous	NULL
RAGE	NULL
signaling	NULL
in	NULL
a	NULL
DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
trans-dominant	NULL
manner	NULL
.	NULL

RAGE	NULL
specificity	NULL
was	NULL
demonstrated	NULL
by	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
RAGE	NULL
mutant	NULL
,	NULL
the	NULL
peptide	NULL
,	NULL
or	NULL
RAGE	NULL
antiserum	NULL
to	NULL
block	NULL
a	NULL
fourfold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
induced	NULL
by	NULL
TNF-	NULL
«	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Involvement	NULL
of	NULL
reactive	NULL
oxygen	NULL
species	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
,	NULL
and	NULL
the	NULL
MAPK	NULL
family	NULL
in	NULL
CML-HSA-mediated	NULL
NF-	NULL
<	NULL
B	NULL
transcriptional	NULL
activation	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
selective	NULL
inhibitors	NULL
of	NULL
potentially	NULL
relevant	NULL
signaling	NULL
molecules	NULL
impinging	NULL
on	NULL
the	NULL
reporter	NULL
response	NULL
.	NULL

Cells	NULL
transfected	NULL
with	NULL
the	NULL
NF-kB	NULL
reporter	NULL
were	NULL
pretreated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
each	NULL
compound	NULL
before	NULL
stimulation	NULL
with	NULL
CML-HSA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
antioxidant	NULL
NAC	NULL
;	NULL
the	NULL
MEK1	NULL
(	NULL
an	NULL
upstream	NULL
kinase	NULL
for	NULL
ERK1/2	NULL
)	NULL
inhibitor	NULL
,	NULL
PD98059	NULL
;	NULL
and	NULL
the	NULL
p38	NULL
inhibitor	NULL
SB203580	NULL
completely	NULL
blocked	NULL
CML-HSA-induced	NULL
NF-kB	NULL
activation	NULL
.	NULL

Similarly	NULL
,	NULL
genistein	NULL
,	NULL
the	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
(	NULL
PTK	NULL
)	NULL
inhibitor	NULL
,	NULL
resulted	NULL
in	NULL
a	NULL
partial	NULL
but	NULL
significant	NULL
reduction	NULL
(	NULL
~35	NULL
%	NULL
)	NULL
in	NULL
reporter	NULL
activation	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
a	NULL
role	NULL
for	NULL
reactive	NULL
oxygen	NULL
species	NULL
,	NULL
PTK	NULL
,	NULL
and	NULL
MAPK	NULL
in	NULL
the	NULL
signaling	NULL
from	NULL
RAGE	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

CML-HSA	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
is	NULL
a	NULL
crucial	NULL
event	NULL
that	NULL
occurs	NULL
rapidly	NULL
and	NULL
at	NULL
a	NULL
very	NULL
early	NULL
stage	NULL
to	NULL
propagate	NULL
initial	NULL
signals	NULL
after	NULL
activation	NULL
of	NULL
many	NULL
receptors	NULL
.	NULL

Since	NULL
genistein	NULL
diminished	NULL
NF-kB	NULL
activation	NULL
by	NULL
CML-HSA	NULL
,	NULL
we	NULL
evaluated	NULL
more	NULL
directly	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
profile	NULL
after	NULL
CML-HSA	NULL
expo-sure	NULL
.	NULL

Stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
CML-HSA	NULL
caused	NULL
rapid	NULL
phosphorylation	NULL
(	NULL
<	NULL
10	NULL
min	NULL
)	NULL
on	NULL
tyrosine	NULL
residues	NULL
of	NULL
several	NULL
proteins	NULL
.	NULL

Prominent	NULL
phosphotyrosine	NULL
polypeptides	NULL
migrated	NULL
at	NULL
75	NULL
,	NULL
85	NULL
,	NULL
and	NULL
125	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
induced	NULL
phosphotyrosine	NULL
signals	NULL
on	NULL
these	NULL
bands	NULL
were	NULL
abolished	NULL
after	NULL
10	NULL
min	NULL
and	NULL
reappeared	NULL
60	NULL
min	NULL
after	NULL
treatment	NULL
.	NULL

Activation	NULL
of	NULL
MAPK	NULL
family	NULL
members	NULL
in	NULL
response	NULL
to	NULL
CML-HSA	NULL
treatment	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
suggest	NULL
that	NULL
CML-HSA-mediated	NULL
signaling	NULL
to	NULL
NF-	NULL
<	NULL
kB	NULL
involves	NULL
the	NULL
MAPK	NULL
family	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
MAPK	NULL
was	NULL
involved	NULL
,	NULL
CML	NULL
exposure	NULL
(	NULL
min	NULL
)	NULL
0	NULL
_	NULL
10	NULL
20	NULL
30	NULL
45	NULL
60	NULL
kDa	NULL
201	NULL
-	NULL
h	NULL
»	NULL
_	NULL
12	NULL
_	NULL
*	NULL
>	NULL
|	NULL
T	NULL
``	NULL
7	NULL
im	NULL
(	NULL
nt	NULL
#	NULL
>	NULL
vith	NULL
41	NULL
-	NULL
'	NULL
i	NULL
'	NULL
1	NULL
%	NULL
31-	NULL
-*	NULL
Yo	NULL
me	NULL
*~	NULL
18	NULL
-	NULL
i	NULL
#	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
profile	NULL
in	NULL
response	NULL
to	NULL
CML-HSA	NULL
ex-posure	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
100	NULL
g/ml	NULL
CML-HSA	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
tyrosine-phospho-rylated	NULL
proteins	NULL
were	NULL
detected	NULL
by	NULL
blotting	NULL
with	NULL
an	NULL
antiphosphotyrosine	NULL
antibody	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1499	NULL
RAGE-MEDIATED	NULL
p38	NULL
MAPK-DEPENDENT	NULL
NF-B	NULL
ACTIVATION	NULL
we	NULL
examined	NULL
MAPK	NULL
activation	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
antibodies	NULL
specific	NULL
to	NULL
the	NULL
active	NULL
forms	NULL
of	NULL
the	NULL
kinases	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
stimulation	NULL
of	NULL
THP-1	NULL
monocytes	NULL
with	NULL
CML-HSA	NULL
enhanced	NULL
ERK1/2	NULL
MAPK	NULL
activities	NULL
approximately	NULL
twofold	NULL
over	NULL
basal	NULL
levels	NULL
.	NULL

CML-HSA-mediated	NULL
ERK	NULL
activity	NULL
peaked	NULL
at	NULL
20	NULL
min	NULL
and	NULL
returned	NULL
to	NULL
basal	NULL
levels	NULL
by	NULL
45	NULL
min	NULL
posttreatment	NULL
.	NULL

Moreover	NULL
,	NULL
incubation	NULL
of	NULL
cells	NULL
with	NULL
PD98059	NULL
for	NULL
30	NULL
min	NULL
before	NULL
CML-HSA	NULL
stimulation	NULL
resulted	NULL
in	NULL
complete	NULL
inhibition	NULL
of	NULL
ERK1/2	NULL
activation	NULL
,	NULL
whereas	NULL
addition	NULL
of	NULL
the	NULL
p38	NULL
inhibitor	NULL
SB203580	NULL
had	NULL
no	NULL
detectable	NULL
effect	NULL
.	NULL

p38	NULL
Kinase	NULL
,	NULL
another	NULL
member	NULL
of	NULL
the	NULL
MAPK	NULL
family	NULL
,	NULL
also	NULL
responded	NULL
to	NULL
CML-HSA	NULL
treatment	NULL
,	NULL
as	NULL
its	NULL
activity	NULL
was	NULL
stimulated	NULL
1.3-	NULL
to	NULL
2	NULL
.	NULL

1-fold	NULL
between	NULL
5	NULL
and	NULL
30	NULL
min	NULL
,	NULL
with	NULL
maximal	NULL
kinase	NULL
activity	NULL
at	NULL
20	NULL
min	NULL
after	NULL
CML-HSA	NULL
exposure	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Like	NULL
ERKs	NULL
,	NULL
p38	NULL
activity	NULL
returned	NULL
to	NULL
basal	NULL
levels	NULL
45	NULL
min	NULL
after	NULL
treatment	NULL
.	NULL

SB203580	NULL
,	NULL
the	NULL
selective	NULL
inhibitor	NULL
of	NULL
p38	NULL
,	NULL
blocked	NULL
>	NULL
80	NULL
%	NULL
of	NULL
the	NULL
p38	NULL
activation	NULL
.	NULL

PD98059	NULL
had	NULL
no	NULL
detectable	NULL
effect	NULL
.	NULL

No	NULL
changes	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
JNK	NULL
activation	NULL
after	NULL
CML-HSA	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

Concentrations	NULL
of	NULL
PD98059	NULL
and	NULL
SB203580	NULL
that	NULL
effectively	NULL
blocked	NULL
the	NULL
NF-kB	NULL
reporter	NULL
response	NULL
did	NULL
not	NULL
affect	NULL
JNK	NULL
activity	NULL
.	NULL

CML-HSA-induced	NULL
NF-KB	NULL
transcriptional	NULL
activation	NULL
requires	NULL
p38	NULL
MAPK	NULL
.	NULL

To	NULL
establish	NULL
a	NULL
direct	NULL
role	NULL
for	NULL
p38	NULL
MAPK	NULL
in	NULL
RAGE	NULL
signaling	NULL
leading	NULL
to	NULL
NF-kB	NULL
transcriptional	NULL
activation	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
NF-kB	NULL
reporter	NULL
and	NULL
an	NULL
expression	NULL
plasmid	NULL
directing	NULL
the	NULL
synthesis	NULL
of	NULL
a	NULL
dominant-negative	NULL
form	NULL
of	NULL
p38	NULL
.	NULL

Overexpression	NULL
of	NULL
the	NULL
kinase-dead	NULL
p38	NULL
mutant	NULL
completely	NULL
blocked	NULL
CML-HSA-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
as	NULL
did	NULL
expression	NULL
of	NULL
an	NULL
IxB	NULL
mutant	NULL
resistant	NULL
to	NULL
phosphorylation-dependent	NULL
degradation	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
)	NULL
.	NULL

To	NULL
further	NULL
verify	NULL
that	NULL
the	NULL
expressed	NULL
p38	NULL
mutant	NULL
competes	NULL
efficiently	NULL
with	NULL
the	NULL
endogenous	NULL
wild-type	NULL
kinase	NULL
,	NULL
we	NULL
also	NULL
measured	NULL
the	NULL
p38	NULL
kinase	NULL
activity	NULL
from	NULL
empty	NULL
vector-transfected	NULL
and	NULL
p38	NULL
mutant-transfected	NULL
cells	NULL
.	NULL

In	NULL
vitro	NULL
kinase	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
transcription	NULL
factor	NULL
ATF-2	NULL
,	NULL
a	NULL
downstream	NULL
target	NULL
of	NULL
p38	NULL
,	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

Although	NULL
total	NULL
p38	NULL
protein	NULL
levels	NULL
were	NULL
elevated	NULL
by	NULL
expressing	NULL
the	NULL
mutant	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
,	NULL
the	NULL
p38	NULL
mutant-containing	NULL
lysate	NULL
had	NULL
much	NULL
less	NULL
kinase	NULL
activity	NULL
compared	NULL
with	NULL
the	NULL
empty	NULL
vector-transfected	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

CML-HSA-induced	NULL
monocytic	NULL
cytokine	NULL
release	NULL
requires	NULL
p38	NULL
MAPK	NULL
and	NULL
NF-B	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
well	NULL
established	NULL
that	NULL
NF-kB	NULL
mediates	NULL
proinflammatory	NULL
responses	NULL
by	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
number	NULL
of	NULL
cytokines	NULL
(	NULL
38,39	NULL
)	NULL
,	NULL
and	NULL
since	NULL
CML-HSA	NULL
induced	NULL
p38-dependent	NULL
NF-kB	NULL
activation	NULL
in	NULL
THP-1	NULL
monocytes	NULL
,	NULL
we	NULL
further	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
p38	NULL
MAPK	NULL
and	NULL
NF-kB	NULL
in	NULL
CML-HSA-induced	NULL
cytokine	NULL
production	NULL
.	NULL

Mock-	NULL
,	NULL
p38	NULL
,	NULL
or	NULL
IxB	NULL
mutant-transfected	NULL
THP-1	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
CML-HSA	NULL
for	NULL
24	NULL
h	NULL
,	NULL
and	NULL
secreted	NULL
cytokines	NULL
were	NULL
measured	NULL
.	NULL

Table	NULL
1	NULL
shows	NULL
that	NULL
CML-HSA	NULL
treatment	NULL
induced	NULL
a	NULL
robust	NULL
secretion	NULL
of	NULL
TNF-	NULL
«	NULL
and	NULL
MCP-1	NULL
(	NULL
~12-	NULL
and	NULL
6-fold	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

IL-1B	NULL
production	NULL
was	NULL
less	NULL
dramatic	NULL
but	NULL
still	NULL
increased	NULL
~3.5-fold	NULL
by	NULL
24	NULL
h.	NULL
Expression	NULL
of	NULL
the	NULL
p38	NULL
dominant-negative	NULL
mutant	NULL
or	NULL
the	NULL
IxB	NULL
mutant	NULL
significantly	NULL
reduced	NULL
the	NULL
CML-HSA-induced	NULL
secretion	NULL
of	NULL
these	NULL
cytokines	NULL
,	NULL
indicating	NULL
that	NULL
p38	NULL
MAPK	NULL
and	NULL
are	NULL
both	NULL
required	NULL
in	NULL
the	NULL
signaling	NULL
pathway	NULL
from	NULL
RAGE	NULL
to	NULL
cytokine	NULL
production	NULL
.	NULL

To	NULL
strengthen	NULL
and	NULL
extend	NULL
this	NULL
obser-vation	NULL
,	NULL
similar	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
peripheral	NULL
blood-derived	NULL
monocytes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
,	NULL
CML-HSA	NULL
1500	NULL
A	NULL
ce	NULL
CML	NULL
exposure	NULL
(	NULL
min	NULL
)	NULL
§	NULL
§	NULL
0	NULL
-	NULL
5	NULL
102030456qua	NULL
ho-ERK	NULL
1	NULL
-	NULL
»	NULL
|	NULL
.	NULL

t	NULL
«	NULL
ork	NULL
Etrllggho-ERK	NULL
;	NULL
»	NULL
dHH	NULL
--	NULL
h	NULL
--	NULL
O	NULL
’	NULL
ERK	NULL
1	NULL
-	NULL
»	NULL
|	NULL
L2	NULL
22	NULL
(	NULL
ERK	NULL
2	NULL
-	NULL
»	NULL
|	NULL
=	NULL
--	NULL
«	NULL
<	NULL
--	NULL
-	NULL
=-	NULL
LL	NULL
ome	NULL
n	NULL
s	NULL
es	NULL
<	NULL
2	NULL
Fold	NULL
activation	NULL
1.0	NULL
12	NULL
1.5	NULL
22	NULL
20	NULL
10	NULL
14	NULL
10	NULL
27	NULL
B	NULL
8	NULL
&	NULL
CML	NULL
exposure	NULL
(	NULL
min	NULL
)	NULL
§	NULL
g	NULL
£	NULL
g	NULL
0	NULL
5	NULL
10	NULL
20	NULL
30	NULL
45	NULL
60	NULL
+	NULL
+	NULL
Phospho-p38	NULL
*	NULL
--	NULL
«	NULL
-o	NULL
sms	NULL
us	NULL
gag	NULL
cme	NULL
os	NULL
gong	NULL
***	NULL
p38	NULL
--	NULL
--	NULL
<	NULL
an	NULL
-a	NULL
»	NULL
42	NULL
Fold	NULL
activation	NULL
1.0	NULL
1.3	NULL
1.5	NULL
21	NULL
1.6	NULL
12	NULL
12	NULL
20	NULL
12	NULL
C	NULL
o	NULL
é	NULL
CML	NULL
exposure	NULL
(	NULL
min	NULL
)	NULL
§	NULL
9	NULL
£	NULL
g	NULL
0	NULL
5	NULL
10	NULL
20	NULL
30	NULL
45	NULL
60	NULL
+	NULL
+	NULL
Phospho-JNK	NULL
«	NULL
-o	NULL
come	NULL
come	NULL
come	NULL
>	NULL
came	NULL
com	NULL
«	NULL
me	NULL
4	NULL
``	NULL
NK	NULL
“	NULL
Wm	NULL
f	NULL
*	NULL
Fold	NULL
activation	NULL
1.0	NULL
1.0	NULL
1.0	NULL
0.9	NULL
11	NULL
11	NULL
1.0	NULL
1.0	NULL
1.0	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

CML-HSA	NULL
treatment	NULL
activates	NULL
MAPK	NULL
family	NULL
members	NULL
ERK1/2	NULL
and	NULL
p38	NULL
but	NULL
not	NULL
JNK	NULL
.	NULL

Samples	NULL
were	NULL
taken	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
after	NULL
100	NULL
pg/ml	NULL
CML-HSA	NULL
exposure	NULL
and	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotting	NULL
analysis	NULL
.	NULL

Upper	NULL
panels	NULL
:	NULL
probed	NULL
with	NULL
an	NULL
antibody	NULL
that	NULL
specifically	NULL
recognizes	NULL
the	NULL
phosphorylated	NULL
forms	NULL
.	NULL

Lower	NULL
panels	NULL
:	NULL
the	NULL
same	NULL
membrane	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
a	NULL
pan	NULL
antibody	NULL
,	NULL
showing	NULL
equal	NULL
protein	NULL
loading	NULL
of	NULL
all	NULL
lanes	NULL
.	NULL

A	NULL
:	NULL
ERK1/2	NULL
;	NULL
B	NULL
:	NULL
p38	NULL
;	NULL
and	NULL
C	NULL
:	NULL
JNK	NULL
.	NULL

To	NULL
test	NULL
the	NULL
effect	NULL
of	NULL
PD98059	NULL
and	NULL
SB203580	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
either	NULL
inhibitor	NULL
for	NULL
30	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
CML-HSA	NULL
exposure	NULL
for	NULL
another	NULL
20	NULL
min	NULL
,	NULL
a	NULL
time	NULL
point	NULL
at	NULL
which	NULL
the	NULL
peak	NULL
activation	NULL
was	NULL
seen	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Densito-metric	NULL
analysis	NULL
for	NULL
kinase	NULL
activation	NULL
by	NULL
CML-HSA	NULL
compared	NULL
with	NULL
the	NULL
basal	NULL
level	NULL
(	NULL
time	NULL
0	NULL
,	NULL
set	NULL
as	NULL
1.0	NULL
)	NULL
is	NULL
indicated	NULL
.	NULL

induced	NULL
an	NULL
approximately	NULL
fourfold	NULL
increase	NULL
in	NULL
TNF-a	NULL
«	NULL
in	NULL
primary	NULL
monocytes	NULL
,	NULL
a	NULL
response	NULL
that	NULL
was	NULL
blocked	NULL
by	NULL
$	NULL
B203580	NULL
and	NULL
PD98059	NULL
.	NULL

DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
C.-H.	NULL
YEH	NULL
AND	NULL
ASSOCIATES	NULL
&	NULL
&	NULL
A	NULL
B	NULL
J	NULL
&	NULL
5	NULL
&	NULL
2	NULL
&	NULL
£	NULL
#	NULL
>	NULL
&	NULL
a	NULL
&	NULL
Pa	NULL
&	NULL
'	NULL
&	NULL
&	NULL
&	NULL
£	NULL
5°	NULL
&	NULL
F	NULL
&	NULL
200	NULL
{	NULL
AZ	NULL
.	NULL

o	NULL
51	NULL
T	NULL
Q	NULL
&	NULL
O	NULL
a	NULL
§	NULL
15904	NULL
B	NULL
*	NULL
d	NULL
©	NULL
3	NULL
o	NULL
100	NULL
j	NULL
a	NULL
&	NULL
a	NULL
-	NULL
>	NULL
|	NULL
ug	NULL
ul	NULL
s	NULL
-	NULL
»	NULL
$	NULL
08	NULL
.	NULL

Bug	NULL
<	NULL
0	NULL
>	NULL
B	NULL
®	NULL
&	NULL
-	NULL
0	NULL
+	NULL
;	NULL
&	NULL
&	NULL
a	NULL
3°	NULL
&	NULL
&	NULL
IB	NULL
:	NULL
o-p38	NULL
a-p-ATF2	NULL
«	NULL
&	NULL
©	NULL
&	NULL
3	NULL
&	NULL
$	NULL
oP	NULL
@	NULL
(	NULL
06	NULL
>	NULL
Q	NULL
N	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Requirement	NULL
of	NULL
p38	NULL
MAPK	NULL
in	NULL
CML-HSA-induced	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activation	NULL
.	NULL

A	NULL
:	NULL
Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
a	NULL
kinase-dead	NULL
p38	NULL
MAPK	NULL
or	NULL
an	NULL
IxB	NULL
dominant-negative	NULL
mutant	NULL
together	NULL
with	NULL
the	NULL
reporter	NULL
then	NULL
treated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
100	NULL
pg/ml	NULL
CML-HSA	NULL
or	NULL
HSA	NULL
,	NULL
and	NULL
results	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
HSA	NULL
treatment	NULL
.	NULL

Data	NULL
are	NULL
the	NULL
means	NULL
+	NULL
SE	NULL
of	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
empty	NULL
vector	NULL
control	NULL
)	NULL
.	NULL

B	NULL
:	NULL
Cell	NULL
lysates	NULL
from	NULL
THP-1	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
transfected	NULL
with	NULL
the	NULL
p38	NULL
mutant	NULL
or	NULL
empty	NULL
vector	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
an	NULL
anti-p38	NULL
antibody	NULL
for	NULL
protein	NULL
level	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
an	NULL
anti-phospho-ATF-2	NULL
antibody	NULL
for	NULL
kinase	NULL
activity	NULL
after	NULL
in	NULL
vitro	NULL
kinase	NULL
reactions	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
results	NULL
of	NULL
our	NULL
experiments	NULL
identify	NULL
a	NULL
signaling	NULL
cascade	NULL
in	NULL
THP-1	NULL
monocytes	NULL
in	NULL
which	NULL
CML-HSA	NULL
binds	NULL
RAGE	NULL
,	NULL
leading	NULL
to	NULL
phosphorylation	NULL
of	NULL
p38	NULL
MAPK	NULL
and	NULL
ERK1/2	NULL
,	NULL
causing	NULL
increased	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
secretion	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
.	NULL

Although	NULL
many	NULL
AGEs	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
including	NULL
pen-tosidine	NULL
,	NULL
methylglyoxal	NULL
,	NULL
pyralline	NULL
,	NULL
and	NULL
imidizalone	NULL
(	NULL
1,3,4,9	NULL
)	NULL
,	NULL
to	NULL
date	NULL
,	NULL
only	NULL
CML	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
an	NULL
adduct	NULL
on	NULL
proteins	NULL
that	NULL
act	NULL
as	NULL
a	NULL
ligand	NULL
for	NULL
RAGE	NULL
(	NULL
83	NULL
)	NULL
.	NULL

Our	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
observations	NULL
that	NULL
1	NULL
)	NULL
RAGE	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
chronic	NULL
cellular	NULL
activation	NULL
and	NULL
tissue	NULL
injury	NULL
by	NULL
serving	NULL
as	NULL
a	NULL
cell-surface	NULL
receptor	NULL
for	NULL
the	NULL
S100/calgranulin	NULL
family	NULL
of	NULL
polypeptides	NULL
that	NULL
are	NULL
released	NULL
from	NULL
activated	NULL
inflammatory	NULL
cells	NULL
and	NULL
accumulate	NULL
at	NULL
sites	NULL
of	NULL
chronic	NULL
inflammation	NULL
(	NULL
6	NULL
)	NULL
;	NULL
2	NULL
)	NULL
AGE-induced	NULL
increased	NULL
endothelial	NULL
cell	NULL
tissue	NULL
factor	NULL
expression	NULL
,	NULL
a	NULL
membrane-bound	NULL
glycoprotein	NULL
that	NULL
initiates	NULL
coagulation	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
factor	NULL
VI/	NULL
TABLE	NULL
1	NULL
CML-HSA-induced	NULL
monocytic	NULL
cytokine	NULL
release	NULL
requires	NULL
p38	NULL
MAPK	NULL
and	NULL
NF-kB	NULL
Cytokine	NULL
production	NULL
(	NULL
pg/ml	NULL
)	NULL
Transfection	NULL
-	NULL
Treatment	NULL
TNF-a	NULL
IL-18	NULL
MCP-1	NULL
Mock	NULL
HSA	NULL
0.6	NULL
+	NULL
0.2	NULL
-	NULL
0.2	NULL
+	NULL
0.1	NULL
74A	NULL
+	NULL
0.2	NULL
Mock	NULL
CMLHSA	NULL
7.3	NULL
+03	NULL
0.7+0.0	NULL
-	NULL
44.3	NULL
+	NULL
0.5	NULL
p38	NULL
mutant	NULL
CML-HSA	NULL
-	NULL
2.5	NULL
+	NULL
0.1*	NULL
0.1	NULL
+	NULL
0.0	NULL
%	NULL
20.7	NULL
+	NULL
1.2*	NULL
IxB	NULL
mutant	NULL
CML-HSA	NULL
-	NULL
2.2	NULL
+	NULL
0.1*	NULL
0.1	NULL
+	NULL
0.0	NULL
%	NULL
25.8	NULL
+	NULL
0.4*	NULL
Data	NULL
are	NULL
normalized	NULL
by	NULL
subtracting	NULL
the	NULL
background	NULL
(	NULL
TNF-	NULL
«	NULL
,	NULL
1.7	NULL
+	NULL
0.2	NULL
pg/ml	NULL
;	NULL
IL-1B	NULL
,	NULL
0.2	NULL
+	NULL
0.1	NULL
pg/ml	NULL
;	NULL
MCP-1	NULL
,	NULL
2.5	NULL
+	NULL
0.6	NULL
pg/ml	NULL
;	NULL
mock	NULL
,	NULL
without	NULL
treatment	NULL
)	NULL
and	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
SE	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
transfected	NULL
and	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
as	NULL
described	NULL
,	NULL
and	NULL
culture	NULL
media	NULL
was	NULL
collected	NULL
for	NULL
cytokine	NULL
measurement	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
mock	NULL
,	NULL
CML-HSA	NULL
treatment	NULL
.	NULL

DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
VIla	NULL
,	NULL
is	NULL
blocked	NULL
by	NULL
RAGE	NULL
antisense	NULL
(	NULL
27	NULL
)	NULL
;	NULL
2	NULL
)	NULL
AGE-RAGE	NULL
interaction	NULL
induces	NULL
cell-associated	NULL
VCAM-1	NULL
expression	NULL
(	NULL
26	NULL
)	NULL
;	NULL
4	NULL
)	NULL
high-molecular	NULL
weight	NULL
hyaluronic	NULL
acid	NULL
blocks	NULL
AGE-induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
and	NULL
proinflammatory	NULL
cytokine	NULL
production	NULL
in	NULL
J774	NULL
mouse	NULL
macrophages	NULL
(	NULL
40	NULL
)	NULL
;	NULL
and	NULL
5	NULL
)	NULL
AGE	NULL
adducts	NULL
increase	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
24,30	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
many	NULL
studies	NULL
have	NULL
shown	NULL
RAGE-induced	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
here	NULL
we	NULL
further	NULL
show	NULL
that	NULL
this	NULL
DNA	NULL
binding	NULL
leads	NULL
to	NULL
increased	NULL
transcription	NULL
of	NULL
NF-kB	NULL
target	NULL
genes	NULL
.	NULL

These	NULL
findings	NULL
,	NULL
together	NULL
with	NULL
the	NULL
observations	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
pleiotropic	NULL
regulator	NULL
of	NULL
many	NULL
``	NULL
re-sponse-to-injury	NULL
``	NULL
genes	NULL
and	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
cell-surface	NULL
receptor	NULL
is	NULL
upregulated	NULL
in	NULL
a	NULL
number	NULL
of	NULL
diverse	NULL
pathologies	NULL
,	NULL
suggest	NULL
a	NULL
central	NULL
role	NULL
for	NULL
RAGE	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
proinflammatory	NULL
and	NULL
prothrombotic	NULL
genes	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
RAGE	NULL
is	NULL
required	NULL
for	NULL
CML	NULL
adducts	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
target	NULL
gene	NULL
transcription	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
studies	NULL
demonstrating	NULL
that	NULL
transient	NULL
transfection	NULL
of	NULL
a	NULL
cDNA-encoding	NULL
RAGE	NULL
lacking	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
imparted	NULL
a	NULL
dominant-negative	NULL
effect	NULL
when	NULL
the	NULL
ligand	NULL
TABLE	NULL
2	NULL
CML-HSA-induced	NULL
TNF-	NULL
«	NULL
release	NULL
in	NULL
peripheral	NULL
monocytes	NULL
is	NULL
sensitive	NULL
to	NULL
5B203580	NULL
and	NULL
PD98059	NULL
Treatment	NULL
TNF-a	NULL
production	NULL
(	NULL
pg/ml	NULL
)	NULL
Sham	NULL
1.9	NULL
+	NULL
0.1	NULL
HSA	NULL
2.8	NULL
+	NULL
0.1	NULL
CML-HSA	NULL
11.0	NULL
+	NULL
0.9	NULL
CML-HSA	NULL
+	NULL
$	NULL
B203580	NULL
3.9	NULL
+	NULL
0.4*	NULL
CML-HSA	NULL
+	NULL
PD98059	NULL
2.2	NULL
+	NULL
0.3	NULL
%	NULL
Data	NULL
are	NULL
the	NULL
means	NULL
+	NULL
SE	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Peripheral	NULL
monocytes	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
as	NULL
described	NULL
,	NULL
and	NULL
culture	NULL
media	NULL
was	NULL
collected	NULL
for	NULL
TNF-	NULL
«	NULL
measurement	NULL
by	NULL
ELISA	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
CML-HSA	NULL
treatment	NULL
.	NULL

1501	NULL
RAGE-MEDIATED	NULL
p38	NULL
MAPK-DEPENDENT	NULL
NF-B	NULL
ACTIVATION	NULL
was	NULL
CML-ovalbumin	NULL
(	NULL
833	NULL
)	NULL
or	NULL
S100B	NULL
(	NULL
a	NULL
member	NULL
of	NULL
the	NULL
S100/	NULL
calgranulin	NULL
family	NULL
)	NULL
(	NULL
6	NULL
)	NULL
.	NULL

A	NULL
dominant-negative	NULL
effect	NULL
of	NULL
the	NULL
RAGE	NULL
cytoplasmic	NULL
tail	NULL
also	NULL
was	NULL
reported	NULL
on	NULL
neurite	NULL
outgrowth	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
N18	NULL
neuroblastoma	NULL
and	NULL
C6	NULL
glioma	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
AGE-modified	NULL
bovine	NULL
serum	NULL
albumin	NULL
and	NULL
amphoterin	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
conserved	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
RAGE	NULL
is	NULL
required	NULL
for	NULL
CML-HSA	NULL
to	NULL
activate	NULL
NF-kB	NULL
,	NULL
only	NULL
some	NULL
of	NULL
the	NULL
signaling	NULL
intermediates	NULL
in	NULL
the	NULL
path	NULL
from	NULL
RAGE	NULL
to	NULL
the	NULL
nucleus	NULL
have	NULL
been	NULL
demonstrated	NULL
.	NULL

Thus	NULL
,	NULL
oxidant	NULL
stress	NULL
(	NULL
24	NULL
)	NULL
,	NULL
PTK	NULL
(	NULL
42	NULL
)	NULL
,	NULL
p21Ras	NULL
,	NULL
and	NULL
ERK1/2	NULL
MAPK	NULL
(	NULL
30	NULL
)	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
AGE-mediated	NULL
signaling	NULL
cascade	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
more	NULL
than	NULL
one	NULL
parallel	NULL
pathway	NULL
can	NULL
be	NULL
activated	NULL
simultaneously	NULL
by	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
RAGE	NULL
(	NULL
41	NULL
)	NULL
.	NULL

In	NULL
that	NULL
study	NULL
,	NULL
it	NULL
was	NULL
demonstrated	NULL
that	NULL
Rac	NULL
and	NULL
Cdc42	NULL
,	NULL
the	NULL
Rho	NULL
family	NULL
small	NULL
GTPases	NULL
,	NULL
were	NULL
responsible	NULL
for	NULL
RAGE-mediated	NULL
neurite	NULL
outgrowth	NULL
induced	NULL
by	NULL
amphoterin	NULL
,	NULL
but	NULL
not	NULL
the	NULL
simultaneous	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B-dependent	NULL
transcription	NULL
,	NULL
which	NULL
was	NULL
dependent	NULL
on	NULL
Ras-MAPK	NULL
pathway	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
CML-HSA	NULL
ligation	NULL
of	NULL
RAGE	NULL
induced	NULL
acute	NULL
tyrosine	NULL
phosphorylation	NULL
followed	NULL
by	NULL
either	NULL
dephos-phorylation	NULL
or	NULL
degradation	NULL
.	NULL

For	NULL
many	NULL
transmembrane	NULL
immunoglobulin-class	NULL
receptors	NULL
,	NULL
signaling	NULL
is	NULL
initiated	NULL
by	NULL
ligand-induced	NULL
aggregation	NULL
that	NULL
activates	NULL
receptor-cou-pled	NULL
tyrosine	NULL
kinases	NULL
(	NULL
43,44	NULL
)	NULL
.	NULL

In	NULL
most	NULL
studies	NULL
of	NULL
mammalian	NULL
receptors	NULL
that	NULL
signal	NULL
by	NULL
coupling	NULL
to	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
or	NULL
that	NULL
contain	NULL
intrinsic	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
,	NULL
the	NULL
earliest	NULL
obligate	NULL
intracellular	NULL
event	NULL
after	NULL
ligand	NULL
engagement	NULL
is	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
45,46	NULL
)	NULL
.	NULL

Although	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
RAGE	NULL
signaling	NULL
,	NULL
no	NULL
consensus	NULL
kinase	NULL
motif	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
RAGE	NULL
intracellular	NULL
domain	NULL
.	NULL

Con-sequently	NULL
,	NULL
RAGE	NULL
probably	NULL
couples	NULL
to	NULL
a	NULL
tyrosine	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
,	NULL
directly	NULL
or	NULL
indirectly	NULL
,	NULL
to	NULL
mediate	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

Currently	NULL
,	NULL
intracellular	NULL
proteins	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
RAGE	NULL
cytoplasmic	NULL
domain	NULL
remain	NULL
unknown	NULL
.	NULL

A	NULL
wide	NULL
variety	NULL
of	NULL
extracellular	NULL
signals	NULL
regulate	NULL
phosphorylation-dependent	NULL
activation	NULL
of	NULL
MAPK	NULL
family	NULL
members	NULL
that	NULL
subsequently	NULL
modulate	NULL
transcriptional	NULL
responses	NULL
altering	NULL
cellular	NULL
function	NULL
in	NULL
normal	NULL
and	NULL
pathological	NULL
set-tings	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
considerable	NULL
cross-talk	NULL
within	NULL
these	NULL
signaling	NULL
cascades	NULL
,	NULL
some	NULL
generalities	NULL
have	NULL
emerged	NULL
regarding	NULL
the	NULL
specific	NULL
types	NULL
of	NULL
information	NULL
that	NULL
are	NULL
processed	NULL
through	NULL
the	NULL
three	NULL
MAPK	NULL
family	NULL
members	NULL
.	NULL

Thus	NULL
,	NULL
ERK	NULL
typically	NULL
mediates	NULL
cell	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
growth	NULL
factors	NULL
,	NULL
whereas	NULL
p38	NULL
and	NULL
JNK	NULL
respond	NULL
to	NULL
cytokines	NULL
and	NULL
cellular	NULL
stress	NULL
inducers	NULL
.	NULL

Previously	NULL
,	NULL
RAGE	NULL
ligands	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
activate	NULL
ERK	NULL
in	NULL
arterial	NULL
smooth	NULL
muscle	NULL
cells	NULL
(	NULL
30,47	NULL
)	NULL
,	NULL
rat	NULL
pheochromocytoma	NULL
PC12	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
renal	NULL
tubulus	NULL
cells	NULL
in	NULL
culture	NULL
(	NULL
48	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
pathway	NULL
is	NULL
common	NULL
across	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

Our	NULL
results	NULL
implicate	NULL
both	NULL
ERK	NULL
and	NULL
p38	NULL
as	NULL
key	NULL
intermediates	NULL
in	NULL
CML-HSA	NULL
activation	NULL
of	NULL
RAGE	NULL
signaling	NULL
leading	NULL
to	NULL
target	NULL
gene	NULL
expression	NULL
in	NULL
a	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
these	NULL
responses	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
activation	NULL
of	NULL
JNK	NULL
,	NULL
the	NULL
third	NULL
MAPK	NULL
family	NULL
member	NULL
.	NULL

Additional	NULL
specificity	NULL
is	NULL
evident	NULL
since	NULL
p388	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
SB203580	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
p38	NULL
isoforms	NULL
must	NULL
mediate	NULL
the	NULL
response	NULL
to	NULL
CML-HSA	NULL
(	NULL
49	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
on	NULL
p38	NULL
appear	NULL
not	NULL
to	NULL
be	NULL
unique	NULL
to	NULL
the	NULL
AGE	NULL
ligand	NULL
used	NULL
,	NULL
CML-HSA	NULL
,	NULL
since	NULL
amphoterin-induced	NULL
RAGE	NULL
signaling	NULL
in	NULL
C6	NULL
glioma	NULL
cells	NULL
activated	NULL
p38	NULL
as	NULL
well	NULL
as	NULL
1502	NULL
p44/p42	NULL
(	NULL
ERK	NULL
)	NULL
and	NULL
stress-activated	NULL
protein	NULL
kinase/JNK	NULL
MAPKs	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
extent	NULL
of	NULL
induction	NULL
for	NULL
ERK1/2	NULL
and	NULL
p38	NULL
was	NULL
comparable	NULL
in	NULL
both	NULL
studies	NULL
.	NULL

Our	NULL
inability	NULL
to	NULL
detect	NULL
JNK	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
CML-HSA	NULL
may	NULL
be	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
cell	NULL
types	NULL
(	NULL
THP-1	NULL
monocytes	NULL
versus	NULL
C6	NULL
glioma	NULL
)	NULL
,	NULL
exposure	NULL
times	NULL
(	NULL
10-60	NULL
vs.	NULL
90	NULL
min	NULL
)	NULL
,	NULL
and	NULL
ligand	NULL
used	NULL
(	NULL
CML-HSA	NULL
versus	NULL
amphoterin	NULL
)	NULL
,	NULL
which	NULL
may	NULL
have	NULL
different	NULL
affinities	NULL
for	NULL
RAGE	NULL
.	NULL

Other	NULL
recent	NULL
reports	NULL
have	NULL
shown	NULL
closely	NULL
related	NULL
results	NULL
;	NULL
CML-HSA	NULL
increased	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
through	NULL
RAGE	NULL
(	NULL
33	NULL
)	NULL
,	NULL
and	NULL
glycated	NULL
serum	NULL
albumin	NULL
stimulated	NULL
ERK	NULL
activity	NULL
and	NULL
NF-	NULL
<	NULL
B	NULL
DNA	NULL
binding	NULL
(	NULL
30	NULL
)	NULL
,	NULL
but	NULL
unfortunately	NULL
,	NULL
p38	NULL
was	NULL
not	NULL
evaluated	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

Mechanisms	NULL
that	NULL
couple	NULL
activation	NULL
of	NULL
MAPK	NULL
to	NULL
NF-kB	NULL
target	NULL
gene	NULL
induction	NULL
are	NULL
complex	NULL
.	NULL

It	NULL
is	NULL
particularly	NULL
important	NULL
to	NULL
note	NULL
that	NULL
NF-kB	NULL
DNA	NULL
binding	NULL
activity	NULL
is	NULL
necessary	NULL
,	NULL
but	NULL
not	NULL
sufficient	NULL
,	NULL
for	NULL
transcription	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
several	NULL
reports	NULL
and	NULL
reviews	NULL
(	NULL
51	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
IxB	NULL
degradation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
were	NULL
insufficient	NULL
for	NULL
TNF-	NULL
and	NULL
IL-1B-induced	NULL
NF-kB-dependent	NULL
transcription	NULL
(	NULL
52	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
inhibition	NULL
of	NULL
TNF-induced	NULL
p38	NULL
activation	NULL
blocked	NULL
NF-kB-dependent	NULL
gene	NULL
expression	NULL
without	NULL
decreasing	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
53	NULL
)	NULL
,	NULL
leading	NULL
to	NULL
speculation	NULL
that	NULL
these	NULL
intermediates	NULL
converge	NULL
at	NULL
a	NULL
more	NULL
distal	NULL
point	NULL
.	NULL

A	NULL
subsequent	NULL
report	NULL
further	NULL
delineated	NULL
a	NULL
mechanism	NULL
wherein	NULL
p38	NULL
phosphorylated	NULL
the	NULL
TATA-binding	NULL
protein	NULL
TFIID	NULL
,	NULL
increasing	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-kB	NULL
(	NULL
54	NULL
)	NULL
,	NULL
stabilizing	NULL
the	NULL
transcription	NULL
complex	NULL
and	NULL
mediating	NULL
gene	NULL
expression	NULL
.	NULL

This	NULL
mechanism	NULL
was	NULL
further	NULL
supported	NULL
by	NULL
observations	NULL
that	NULL
inhibitors	NULL
of	NULL
p38	NULL
and	NULL
ERKs	NULL
cooperatively	NULL
regulated	NULL
the	NULL
transactivation	NULL
potential	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
increased	NULL
DNA	NULL
binding	NULL
activity	NULL
shown	NULL
here	NULL
and	NULL
by	NULL
others	NULL
is	NULL
only	NULL
an	NULL
intermediate	NULL
readout	NULL
of	NULL
RAGE	NULL
signaling	NULL
and	NULL
illustrates	NULL
the	NULL
importance	NULL
of	NULL
analyzing	NULL
target	NULL
gene	NULL
expression	NULL
,	NULL
as	NULL
we	NULL
report	NULL
here	NULL
,	NULL
for	NULL
secretion	NULL
of	NULL
the	NULL
cytokines	NULL
IL-1B	NULL
,	NULL
TNF-	NULL
«	NULL
@	NULL
,	NULL
and	NULL
MCP-1	NULL
.	NULL

Finally	NULL
,	NULL
our	NULL
observations	NULL
that	NULL
both	NULL
p38	NULL
and	NULL
ERK	NULL
mediate	NULL
RAGE-dependent	NULL
NF-kB	NULL
target	NULL
gene	NULL
induction	NULL
suggest	NULL
that	NULL
RAGE	NULL
may	NULL
be	NULL
a	NULL
pleiotropic	NULL
integrator	NULL
of	NULL
AGEs	NULL
that	NULL
signal	NULL
both	NULL
growth	NULL
factor-like	NULL
proliferative	NULL
responses	NULL
as	NULL
well	NULL
as	NULL
cytokine-like	NULL
proinflammatory	NULL
responses	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
demonstrate	NULL
that	NULL
p38	NULL
activation	NULL
is	NULL
necessary	NULL
for	NULL
CML-HSA-mediated	NULL
RAGE-dependent	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
induction	NULL
of	NULL
target	NULL
gene	NULL
expression	NULL
,	NULL
and	NULL
secretion	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
from	NULL
monocytes	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
a	NULL
RAGE	NULL
signaling	NULL
axis	NULL
involving	NULL
p38	NULL
extends	NULL
our	NULL
understanding	NULL
of	NULL
AGE-induced	NULL
cellular	NULL
dysfunction	NULL
and	NULL
provides	NULL
a	NULL
possible	NULL
mechanism	NULL
for	NULL
p38	NULL
involvement	NULL
in	NULL
inflammation	NULL
,	NULL
arthritis	NULL
,	NULL
septic	NULL
shock	NULL
,	NULL
and	NULL
myocardial	NULL
dysfunction	NULL
after	NULL
ischemia	NULL
(	NULL
56-59	NULL
)	NULL
.	NULL

Further-more	NULL
,	NULL
since	NULL
AGEs-particularly	NULL
CML	NULL
adducts-are	NULL
prevalent	NULL
in	NULL
diseases	NULL
such	NULL
as	NULL
diabetes	NULL
,	NULL
renal	NULL
failure	NULL
,	NULL
chronic	NULL
inflammation	NULL
,	NULL
and	NULL
Alzheimer	NULL
's	NULL
disease	NULL
(	NULL
6,32,33,60	NULL
)	NULL
,	NULL
our	NULL
findings	NULL
may	NULL
provide	NULL
another	NULL
pathophysiologically	NULL
relevant	NULL
mechanism	NULL
linked	NULL
to	NULL
these	NULL
disorders	NULL
.	NULL

Understanding	NULL
the	NULL
integrative	NULL
aspects	NULL
of	NULL
RAGE	NULL
in	NULL
the	NULL
diverse	NULL
pathologies	NULL
of	NULL
AGEs	NULL
provides	NULL
a	NULL
key	NULL
challenge	NULL
for	NULL
future	NULL
studies	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Dr.	NULL
Kaijun	NULL
Ren	NULL
(	NULL
Chemistry	NULL
Department	NULL
at	NULL
Texas	NULL
Biotechnology	NULL
Corporation	NULL
)	NULL
for	NULL
the	NULL
synthesis	NULL
of	NULL
peptides	NULL
used	NULL
in	NULL
the	NULL
RAGE	NULL
inhibition	NULL
studies	NULL
,	NULL
and	NULL
Drs	NULL
.	NULL

Roger	NULL
Davis	NULL
(	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
at	NULL
the	NULL
University	NULL
of	NULL
DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
C.-H.	NULL
YEH	NULL
AND	NULL
ASSOCIATES	NULL
Massachusetts	NULL
Medical	NULL
Center	NULL
,	NULL
Worcester	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
Chung	NULL
Y.	NULL
Hsu	NULL
(	NULL
Washington	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
for	NULL
the	NULL
p38	NULL
kinase-dead	NULL
and	NULL
IxB	NULL
dominant-negative	NULL
mutants	NULL
,	NULL
respectively	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

2	NULL
.	NULL

8	NULL
.	NULL

~	NULL
10	NULL
.	NULL

1	NULL
12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

Brownlee	NULL
M	NULL
:	NULL
Advanced	NULL
protein	NULL
glycosylation	NULL
in	NULL
diabetes	NULL
and	NULL
aging	NULL
.	NULL

Annu	NULL
Rev	NULL
Med	NULL
46:223-234	NULL
,	NULL
1995	NULL
Bucala	NULL
R	NULL
,	NULL
Cerami	NULL
A	NULL
:	NULL
Advanced	NULL
glycosylation	NULL
:	NULL
chemistry	NULL
,	NULL
biology	NULL
,	NULL
and	NULL
implications	NULL
for	NULL
diabetes	NULL
and	NULL
aging	NULL
.	NULL

Adv	NULL
Pharmacol	NULL
23:1-34	NULL
,	NULL
1992	NULL
Viassara	NULL
H	NULL
,	NULL
Bucala	NULL
R	NULL
,	NULL
Striker	NULL
L	NULL
:	NULL
Pathogenic	NULL
effects	NULL
of	NULL
advanced	NULL
glycosylation	NULL
:	NULL
biochemical	NULL
,	NULL
biologic	NULL
,	NULL
and	NULL
clinical	NULL
implications	NULL
for	NULL
diabetes	NULL
and	NULL
aging	NULL
.	NULL

Lab	NULL
Invest	NULL
70:138-151	NULL
,	NULL
1994	NULL
Thornalley	NULL
PJ	NULL
:	NULL
Cell	NULL
activation	NULL
by	NULL
glycated	NULL
proteins	NULL
:	NULL
AGE	NULL
receptors	NULL
,	NULL
receptor	NULL
recognition	NULL
factors	NULL
and	NULL
functional	NULL
classification	NULL
of	NULL
AGEs	NULL
.	NULL

Cell	NULL
Mol	NULL
Biol	NULL
44:1013-1023	NULL
,	NULL
1998	NULL
Schmidt	NULL
AM	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Wautier	NULL
JL	NULL
,	NULL
Stem	NULL
D	NULL
:	NULL
Activation	NULL
of	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
chronic	NULL
vascular	NULL
dysfunction	NULL
in	NULL
diabetic	NULL
vasculopathy	NULL
and	NULL
atherosclerosis	NULL
.	NULL

Circ	NULL
Res	NULL
84:489-497	NULL
,	NULL
1999	NULL
Hofmann	NULL
MA	NULL
,	NULL
Drury	NULL
S	NULL
,	NULL
Fu	NULL
C	NULL
,	NULL
Qu	NULL
W	NULL
,	NULL
Taguchi	NULL
A	NULL
,	NULL
Lu	NULL
Y	NULL
,	NULL
Avila	NULL
C	NULL
,	NULL
Kambham	NULL
N	NULL
,	NULL
Bierhaus	NULL
A	NULL
,	NULL
Nawroth	NULL
P	NULL
,	NULL
Neurath	NULL
MF	NULL
,	NULL
Slattery	NULL
T	NULL
,	NULL
Beach	NULL
D	NULL
,	NULL
McClary	NULL
J	NULL
,	NULL
Nagashima	NULL
M	NULL
,	NULL
Morser	NULL
J	NULL
,	NULL
Stem	NULL
D	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
RAGE	NULL
mediates	NULL
a	NULL
novel	NULL
proinflammatory	NULL
axis	NULL
:	NULL
a	NULL
central	NULL
cell	NULL
surface	NULL
receptor	NULL
for	NULL
S100/calgranulin	NULL
polypeptides	NULL
.	NULL

Cell	NULL
97:889-901	NULL
,	NULL
1999	NULL
Yan	NULL
SD	NULL
,	NULL
Chen	NULL
X	NULL
,	NULL
Fu	NULL
J	NULL
,	NULL
Chen	NULL
M	NULL
,	NULL
Zhu	NULL
H	NULL
,	NULL
Roher	NULL
A	NULL
,	NULL
Slattery	NULL
T	NULL
,	NULL
Zhao	NULL
L	NULL
,	NULL
Nagashima	NULL
M	NULL
,	NULL
Morser	NULL
J	NULL
,	NULL
Migheli	NULL
A	NULL
,	NULL
Nawroth	NULL
P	NULL
,	NULL
Stem	NULL
D	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
RAGE	NULL
and	NULL
amyloid-beta	NULL
peptide	NULL
neurotoxicity	NULL
in	NULL
Alzheimer	NULL
's	NULL
disease	NULL
.	NULL

Nature	NULL
382:685-691	NULL
,	NULL
1996	NULL
Niwa	NULL
T	NULL
,	NULL
Sato	NULL
M	NULL
,	NULL
Katsuzaki	NULL
T	NULL
,	NULL
Tomoo	NULL
T	NULL
,	NULL
Miyazaki	NULL
T	NULL
,	NULL
Tatemichi	NULL
N	NULL
,	NULL
Takei	NULL
Y	NULL
,	NULL
Kondo	NULL
T	NULL
:	NULL
Amyloid	NULL
beta	NULL
2-microglobulin	NULL
is	NULL
modified	NULL
with	NULL
N	NULL
epsilon-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
in	NULL
dialysis-related	NULL
amyloidosis	NULL
.	NULL

Kidney	NULL
Int	NULL
50:1303-1309	NULL
,	NULL
1996	NULL
.	NULL

Viassara	NULL
H	NULL
:	NULL
Recent	NULL
progress	NULL
in	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
and	NULL
diabetic	NULL
complications	NULL
.	NULL

Diabetes	NULL
46	NULL
(	NULL
Suppl	NULL
.	NULL

2	NULL
)	NULL
:519-525	NULL
,	NULL
1997	NULL
Hammes	NULL
HP	NULL
,	NULL
Martin	NULL
S	NULL
,	NULL
Federlin	NULL
K	NULL
,	NULL
Geisen	NULL
K	NULL
,	NULL
Brownlee	NULL
M	NULL
:	NULL
Aminoguanidine	NULL
treatment	NULL
inhibits	NULL
the	NULL
development	NULL
of	NULL
experimental	NULL
diabetic	NULL
retinopathy	NULL
.	NULL

Proc	NULL
Nail	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
88:11555-11558	NULL
,	NULL
1991	NULL
.	NULL

Edelstein	NULL
D	NULL
,	NULL
Brownlee	NULL
M	NULL
:	NULL
Aminoguanidine	NULL
ameliorates	NULL
albuminuria	NULL
in	NULL
diabetic	NULL
hypertensive	NULL
rats	NULL
.	NULL

Diabetologia	NULL
35:96-97	NULL
,	NULL
1992	NULL
Schmidt	NULL
AM	NULL
,	NULL
Vianna	NULL
M	NULL
,	NULL
Gerlach	NULL
M	NULL
,	NULL
Brett	NULL
J	NULL
,	NULL
Ryan	NULL
J	NULL
,	NULL
Kao	NULL
J	NULL
,	NULL
Esposito	NULL
C	NULL
,	NULL
Hegarty	NULL
H	NULL
,	NULL
Hurley	NULL
W	NULL
,	NULL
Clauss	NULL
M	NULL
,	NULL
Wand	NULL
F	NULL
,	NULL
Pan	NULL
Y-C	NULL
,	NULL
Tsang	NULL
TC	NULL
,	NULL
Stem	NULL
D	NULL
:	NULL
Isolation	NULL
and	NULL
characterization	NULL
of	NULL
two	NULL
binding	NULL
proteins	NULL
for	NULL
advanced	NULL
glycosylation	NULL
end	NULL
products	NULL
from	NULL
bovine	NULL
lung	NULL
which	NULL
are	NULL
present	NULL
on	NULL
the	NULL
endothelial	NULL
cell	NULL
surface	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
267:14987-14997	NULL
,	NULL
1992	NULL
Yang	NULL
Z	NULL
,	NULL
Makita	NULL
Z	NULL
,	NULL
Horii	NULL
Y	NULL
,	NULL
Brunelle	NULL
S	NULL
,	NULL
Cerami	NULL
A	NULL
,	NULL
Sehajpal	NULL
P	NULL
,	NULL
Suthanthiran	NULL
M	NULL
,	NULL
Vlassara	NULL
H	NULL
:	NULL
Two	NULL
novel	NULL
rat	NULL
liver	NULL
membrane	NULL
proteins	NULL
that	NULL
bind	NULL
advanced	NULL
glycosylation	NULL
endproducts	NULL
:	NULL
relationship	NULL
to	NULL
macrophage	NULL
receptor	NULL
for	NULL
glu-cose-modified	NULL
proteins	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
174:515-524	NULL
,	NULL
1991	NULL
Li	NULL
YM	NULL
,	NULL
Mitsuhashi	NULL
T	NULL
,	NULL
Wojciechowicz	NULL
D	NULL
,	NULL
Shimizu	NULL
N	NULL
,	NULL
Li	NULL
J	NULL
,	NULL
Stitt	NULL
A	NULL
,	NULL
He	NULL
C	NULL
,	NULL
Banerjee	NULL
D	NULL
,	NULL
Viassara	NULL
H	NULL
:	NULL
Molecular	NULL
identity	NULL
and	NULL
cellular	NULL
distribution	NULL
of	NULL
advanced	NULL
glycation	NULL
endproduct	NULL
receptors	NULL
:	NULL
relationship	NULL
of	NULL
p60	NULL
to	NULL
OST-48	NULL
and	NULL
p90	NULL
to	NULL
80K-H	NULL
membrane	NULL
proteins	NULL
.	NULL

Proc	NULL
NaH	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
93:11047-11052	NULL
,	NULL
1991	NULL
Viassara	NULL
H	NULL
,	NULL
Li	NULL
YM	NULL
,	NULL
Imani	NULL
F	NULL
,	NULL
Wojciechowicz	NULL
D	NULL
,	NULL
Yang	NULL
Z	NULL
,	NULL
Liu	NULL
FT	NULL
,	NULL
Cerami	NULL
A	NULL
:	NULL
Molecular	NULL
identity	NULL
and	NULL
cellular	NULL
distribution	NULL
of	NULL
advanced	NULL
glycation	NULL
endproduct	NULL
receptors	NULL
:	NULL
relationship	NULL
of	NULL
p60	NULL
to	NULL
OST-48	NULL
and	NULL
p90	NULL
to	NULL
80K-H	NULL
membrane	NULL
proteins	NULL
.	NULL

Mol	NULL
Med	NULL
1:634-646	NULL
,	NULL
1995	NULL
Li	NULL
YM	NULL
,	NULL
Tan	NULL
AX	NULL
,	NULL
Viassara	NULL
H	NULL
;	NULL
Antibacterial	NULL
activity	NULL
of	NULL
lysozyme	NULL
and	NULL
lactoferrin	NULL
is	NULL
inhibited	NULL
by	NULL
binding	NULL
of	NULL
advanced	NULL
glycation-modified	NULL
proteins	NULL
to	NULL
a	NULL
conserved	NULL
motif	NULL
.	NULL

Nat	NULL
Med	NULL
1:1057-1061	NULL
,	NULL
1995	NULL
Neeper	NULL
M	NULL
,	NULL
Schmidt	NULL
AM	NULL
,	NULL
Brett	NULL
J	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Wang	NULL
F	NULL
,	NULL
Pan	NULL
YC	NULL
,	NULL
Elliston	NULL
K	NULL
,	NULL
Stem	NULL
D	NULL
,	NULL
Shaw	NULL
A	NULL
:	NULL
Cloning	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
cell	NULL
surface	NULL
receptor	NULL
for	NULL
advanced	NULL
glycosylation	NULL
end	NULL
products	NULL
of	NULL
proteins	NULL
.	NULL

J	NULL
Bio	NULL
!	NULL

Chem	NULL
267:14998-15004	NULL
,	NULL
1992	NULL
Brett	NULL
J	NULL
,	NULL
Schmidt	NULL
AM	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Zou	NULL
YS	NULL
,	NULL
Weidman	NULL
E	NULL
,	NULL
Pinsky	NULL
D	NULL
,	NULL
Nowygrod	NULL
R	NULL
,	NULL
Neeper	NULL
M	NULL
,	NULL
Przysiecki	NULL
C	NULL
,	NULL
Shaw	NULL
A	NULL
:	NULL
Survey	NULL
of	NULL
the	NULL
distribution	NULL
of	NULL
a	NULL
newly	NULL
characterized	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
in	NULL
tissues	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
143:1699-1712	NULL
,	NULL
1993	NULL
Schmidt	NULL
AM	NULL
,	NULL
Hori	NULL
O	NULL
,	NULL
Brett	NULL
J	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Wautier	NULL
JL	NULL
,	NULL
Stem	NULL
D	NULL
:	NULL
Cellular	NULL
receptors	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
:	NULL
implications	NULL
for	NULL
induction	NULL
of	NULL
oxidant	NULL
stress	NULL
and	NULL
cellular	NULL
dysfunction	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
vascular	NULL
lesions	NULL
.	NULL

Arterioscler	NULL
Thromb	NULL
14:1521-1528	NULL
,	NULL
1994	NULL
Schmidt	NULL
AM	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Stem	NULL
DM	NULL
:	NULL
The	NULL
dark	NULL
side	NULL
of	NULL
glucose	NULL
.	NULL

Nat	NULL
Med	NULL
1:1002-1004	NULL
,	NULL
1995	NULL
DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL
21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

82	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

Miyata	NULL
T	NULL
,	NULL
Hori	NULL
O	NULL
,	NULL
Zhang	NULL
J	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Ferran	NULL
L	NULL
,	NULL
lida	NULL
Y	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
The	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
(	NULL
RAGE	NULL
)	NULL
is	NULL
a	NULL
central	NULL
mediator	NULL
of	NULL
the	NULL
interaction	NULL
of	NULL
AGE-B2	NULL
microglobulin	NULL
with	NULL
human	NULL
mononuclear	NULL
phagocytes	NULL
via	NULL
an	NULL
oxidant-sensitive	NULL
pathway	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
dialysis-related	NULL
amyloidosis	NULL
.	NULL

J	NULL
Clin	NULL
Imvest	NULL
98:1088-1094	NULL
,	NULL
1996	NULL
Wautier	NULL
JL	NULL
,	NULL
Zoukourian	NULL
C	NULL
,	NULL
Chappey	NULL
O	NULL
,	NULL
Wautier	NULL
MP	NULL
,	NULL
Guillausseau	NULL
PJ	NULL
,	NULL
Cao	NULL
R	NULL
,	NULL
Hori	NULL
O	NULL
,	NULL
Stem	NULL
D	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
Receptormediated	NULL
endothelial	NULL
cell	NULL
dysfunction	NULL
in	NULL
diabetic	NULL
vasculopathy	NULL
:	NULL
soluble	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
blocks	NULL
hyperpermeability	NULL
in	NULL
diabetic	NULL
rats	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
97:238-2483	NULL
,	NULL
1996	NULL
Park	NULL
L	NULL
,	NULL
Raman	NULL
KG	NULL
,	NULL
Lee	NULL
J	NULL
,	NULL
Lu	NULL
Y	NULL
,	NULL
Ferran	NULL
LJ	NULL
Jr	NULL
,	NULL
Chow	NULL
WS	NULL
,	NULL
Stem	NULL
D	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
Suppression	NULL
of	NULL
accelerated	NULL
diabetic	NULL
atherosclerosis	NULL
by	NULL
the	NULL
soluble	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
endproducts	NULL
.	NULL

Nat	NULL
Med	NULL
4:1025-1031	NULL
,	NULL
1998	NULL
Yan	NULL
SD	NULL
,	NULL
Schmidt	NULL
AM	NULL
,	NULL
Anderson	NULL
GM	NULL
,	NULL
Zhang	NULL
J	NULL
,	NULL
Brett	NULL
J	NULL
,	NULL
Zou	NULL
YS	NULL
,	NULL
Pinsky	NULL
D	NULL
,	NULL
Stem	NULL
D	NULL
:	NULL
Enhanced	NULL
cellular	NULL
oxidant	NULL
stress	NULL
by	NULL
the	NULL
interaction	NULL
of	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
with	NULL
their	NULL
receptors/binding	NULL
proteins	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:9889-9897	NULL
,	NULL
1994	NULL
.	NULL

Lavrovsky	NULL
Y	NULL
,	NULL
Schwartzman	NULL
ML	NULL
,	NULL
Levere	NULL
RD	NULL
,	NULL
Kappas	NULL
A	NULL
,	NULL
Abraham	NULL
NG	NULL
:	NULL
Identification	NULL
of	NULL
binding	NULL
sites	NULL
for	NULL
transcription	NULL
factors	NULL
NF-kB	NULL
and	NULL
AP-2	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
human	NULL
heme	NULL
oxygenase	NULL
1	NULL
gene	NULL
.	NULL

Proc	NULL
NaHl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
91:5987-5991	NULL
,	NULL
1994	NULL
Schmidt	NULL
AM	NULL
,	NULL
Hori	NULL
0	NULL
,	NULL
Chen	NULL
JX	NULL
,	NULL
Li	NULL
JF	NULL
,	NULL
Crandall	NULL
J	NULL
,	NULL
Zhang	NULL
J	NULL
,	NULL
Cao	NULL
R	NULL
,	NULL
Yan	NULL
SD	NULL
,	NULL
Brett	NULL
J	NULL
,	NULL
Stern	NULL
D	NULL
:	NULL
Advanced	NULL
glycation	NULL
endproducts	NULL
interacting	NULL
with	NULL
their	NULL
endothelial	NULL
receptor	NULL
induce	NULL
expression	NULL
of	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
VCAM-1	NULL
)	NULL
in	NULL
cultured	NULL
human	NULL
endothelial	NULL
cells	NULL
and	NULL
in	NULL
mice	NULL
:	NULL
a	NULL
potential	NULL
mechanism	NULL
for	NULL
the	NULL
accelerated	NULL
vasculopathy	NULL
of	NULL
diabetes	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
96:1395-1403	NULL
,	NULL
1995	NULL
Bierhaus	NULL
A	NULL
,	NULL
Iimer	NULL
T	NULL
,	NULL
Kasper	NULL
M	NULL
,	NULL
Luther	NULL
T	NULL
,	NULL
Quehenberger	NULL
P	NULL
,	NULL
Tritschler	NULL
H	NULL
,	NULL
Wahl	NULL
P	NULL
,	NULL
Ziegler	NULL
R	NULL
,	NULL
Muller	NULL
M	NULL
,	NULL
Nawroth	NULL
PP	NULL
:	NULL
Advanced	NULL
glycation	NULL
end	NULL
product	NULL
(	NULL
AGE	NULL
)	NULL
-mediated	NULL
induction	NULL
of	NULL
tissue	NULL
factor	NULL
in	NULL
cultured	NULL
endothelial	NULL
cells	NULL
is	NULL
dependent	NULL
on	NULL
RAGE	NULL
.	NULL

Circulation	NULL
96:2262-2271	NULL
,	NULL
1997	NULL
.	NULL

Bierhaus	NULL
A	NULL
,	NULL
Ziegler	NULL
R	NULL
,	NULL
Nawroth	NULL
PP	NULL
:	NULL
Molecular	NULL
mechanisms	NULL
of	NULL
diabetic	NULL
angiopathy	NULL
:	NULL
clues	NULL
for	NULL
innovative	NULL
therapeutic	NULL
interventions	NULL
.	NULL

Horm	NULL
Res	NULL
50	NULL
(	NULL
Suppl	NULL
.	NULL

1	NULL
)	NULL
:1-5	NULL
,	NULL
1998	NULL
Li	NULL
J	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
Characterization	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
the	NULL
promoter	NULL
of	NULL
RAGE	NULL
,	NULL
the	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272	NULL
;	NULL
16498-16506	NULL
,	NULL
1997	NULL
Lander	NULL
HM	NULL
,	NULL
Tauras	NULL
JM	NULL
,	NULL
Ogiste	NULL
JS	NULL
,	NULL
Hori	NULL
O	NULL
,	NULL
Moss	NULL
RA	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
Activation	NULL
of	NULL
the	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
triggers	NULL
a	NULL
p2l	NULL
(	NULL
ras	NULL
)	NULL
-dependent	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathway	NULL
regulated	NULL
by	NULL
oxidant	NULL
stress	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:17810-17814	NULL
,	NULL
1997	NULL
Horie	NULL
K	NULL
,	NULL
Miyata	NULL
T	NULL
,	NULL
Maeda	NULL
K	NULL
,	NULL
Miyata	NULL
S	NULL
,	NULL
Sugiyama	NULL
S	NULL
,	NULL
Sakai	NULL
H	NULL
,	NULL
Strihou	NULL
CY	NULL
,	NULL
Monnier	NULL
VM	NULL
,	NULL
Witztum	NULL
JL	NULL
,	NULL
Kurokawa	NULL
K	NULL
:	NULL
Immunohistochemical	NULL
colocaliza-tion	NULL
of	NULL
glycoxidation	NULL
products	NULL
and	NULL
lipid	NULL
peroxidation	NULL
products	NULL
in	NULL
diabetic	NULL
renal	NULL
glomerular	NULL
lesions	NULL
:	NULL
implication	NULL
for	NULL
glycoxidative	NULL
stress	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
diabetic	NULL
nephropathy	NULL
.	NULL

J	NULL
Clin	NULL
Imvest	NULL
100:2995-3004	NULL
,	NULL
1997	NULL
Schleicher	NULL
ED	NULL
,	NULL
Wagner	NULL
E	NULL
,	NULL
Nerlich	NULL
AG	NULL
:	NULL
Increased	NULL
accumulation	NULL
of	NULL
the	NULL
glycoxidation	NULL
product	NULL
N	NULL
(	NULL
epsilon	NULL
}	NULL
-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
in	NULL
human	NULL
tissues	NULL
in	NULL
diabetes	NULL
and	NULL
aging	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
99:457-468	NULL
,	NULL
1997	NULL
Kislinger	NULL
T	NULL
,	NULL
Fu	NULL
C	NULL
,	NULL
Huber	NULL
B	NULL
,	NULL
Qu	NULL
W	NULL
,	NULL
Taguchi	NULL
A	NULL
,	NULL
Du-Yan	NULL
S	NULL
,	NULL
Hofmann	NULL
M	NULL
,	NULL
Yan	NULL
SF	NULL
,	NULL
Pischetsrieder	NULL
M	NULL
,	NULL
Stern	NULL
D	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
N	NULL
(	NULL
epsilon	NULL
}	NULL
-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
adducts	NULL
of	NULL
proteins	NULL
are	NULL
ligands	NULL
for	NULL
receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
that	NULL
activate	NULL
cell	NULL
signaling	NULL
pathways	NULL
and	NULL
modulate	NULL
gene	NULL
expression	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
274:31740-31749	NULL
,	NULL
1999	NULL
Ikeda	NULL
K	NULL
,	NULL
Higashi	NULL
T	NULL
,	NULL
Sano	NULL
H	NULL
,	NULL
Jinnouchi	NULL
Y	NULL
,	NULL
Yoshida	NULL
M	NULL
,	NULL
Araki	NULL
T	NULL
,	NULL
Ueda	NULL
S	NULL
,	NULL
Horiuchi	NULL
S	NULL
:	NULL
;	NULL
N	NULL
(	NULL
epsilon	NULL
)	NULL
}	NULL
-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
protein	NULL
adduct	NULL
is	NULL
a	NULL
major	NULL
immunological	NULL
epitope	NULL
in	NULL
proteins	NULL
modified	NULL
with	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
of	NULL
the	NULL
Maillard	NULL
reaction	NULL
.	NULL

Biochemistry	NULL
35:8075-8083	NULL
,	NULL
1996	NULL
Kanof	NULL
ME	NULL
,	NULL
Smith	NULL
PD	NULL
,	NULL
Zola	NULL
H	NULL
:	NULL
Preparation	NULL
of	NULL
human	NULL
mononuclear	NULL
cell	NULL
populations	NULL
and	NULL
subpopulations	NULL
.	NULL

In	NULL
Current	NULL
Protocols	NULL
in	NULL
Immunology	NULL
.	NULL

Coligan	NULL
JE	NULL
,	NULL
Kruisbeek	NULL
AM	NULL
,	NULL
Margulies	NULL
DH	NULL
,	NULL
Shevach	NULL
EM	NULL
,	NULL
Strober	NULL
W	NULL
,	NULL
Eds	NULL
.	NULL

New	NULL
York	NULL
,	NULL
Greene	NULL
Publishing	NULL
and	NULL
John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
p.	NULL
7.1.1-7.1.7	NULL
,	NULL
1996	NULL
Shirakawa	NULL
F	NULL
,	NULL
Saito	NULL
K	NULL
,	NULL
Bonagura	NULL
CA	NULL
,	NULL
Galson	NULL
DL	NULL
,	NULL
Fenton	NULL
MJ	NULL
,	NULL
Webb	NULL
AC	NULL
,	NULL
Auron	NULL
PE	NULL
:	NULL
The	NULL
human	NULL
prointerleukin	NULL
1	NULL
beta	NULL
gene	NULL
requires	NULL
DNA	NULL
sequences	NULL
both	NULL
proximal	NULL
and	NULL
distal	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
for	NULL
tissue-specific	NULL
induction	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
13:1332-1344	NULL
,	NULL
1998	NULL
Schreiber	NULL
E	NULL
,	NULL
Matthias	NULL
P	NULL
,	NULL
Muller	NULL
MM	NULL
,	NULL
Schaffner	NULL
W	NULL
:	NULL
Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
``	NULL
mini-extracts	NULL
,	NULL
``	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
7:4221-4229	NULL
,	NULL
1988	NULL
Beg	NULL
AA	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
An	NULL
essential	NULL
role	NULL
for	NULL
NF-kB	NULL
in	NULL
preventing	NULL
TNF-	NULL
«	NULL
-induced	NULL
cell	NULL
death	NULL
.	NULL

Science	NULL
274:782-784	NULL
,	NULL
1996	NULL
Miagkov	NULL
AV	NULL
,	NULL
Kovalenko	NULL
DV	NULL
,	NULL
Brown	NULL
CE	NULL
,	NULL
Didsbury	NULL
JR	NULL
,	NULL
Cogswell	NULL
JP	NULL
,	NULL
Stimpson	NULL
SA	NULL
,	NULL
Baldwin	NULL
AS	NULL
,	NULL
Makarov	NULL
SS	NULL
:	NULL
NF-kB	NULL
activation	NULL
provides	NULL
the	NULL
potential	NULL
link	NULL
between	NULL
inflammation	NULL
and	NULL
hyperplasia	NULL
in	NULL
the	NULL
arthritic	NULL
joint	NULL
.	NULL

Proc	NULL
Nail	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
95:13859-13864	NULL
,	NULL
1998	NULL
Neumann	NULL
A	NULL
,	NULL
Schinzel	NULL
R	NULL
,	NULL
Palm	NULL
D	NULL
,	NULL
Riederer	NULL
P	NULL
,	NULL
Munch	NULL
G	NULL
:	NULL
High	NULL
molecular	NULL
1503	NULL
RAGE-MEDIATED	NULL
p38	NULL
MAPK-DEPENDENT	NULL
NF-B	NULL
ACTIVATION	NULL
41	NULL
.	NULL

42	NULL
.	NULL

48	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50.	NULL
weight	NULL
hyaluronic	NULL
acid	NULL
inhibits	NULL
advanced	NULL
glycation	NULL
endproduct-induced	NULL
NF-xB	NULL
activation	NULL
and	NULL
cytokine	NULL
expression	NULL
.	NULL

FEBS	NULL
Lei	NULL
?	NULL

453:283-287	NULL
,	NULL
1999	NULL
Huttunen	NULL
HJ	NULL
,	NULL
Fages	NULL
C	NULL
,	NULL
Rauvala	NULL
H	NULL
;	NULL
Receptor	NULL
for	NULL
advanced	NULL
glycation	NULL
end	NULL
products	NULL
(	NULL
RAGE	NULL
)	NULL
mediated	NULL
neurite	NULL
outgrowth	NULL
and	NULL
activation	NULL
of	NULL
NF-kB	NULL
require	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
receptor	NULL
but	NULL
different	NULL
downstream	NULL
signaling	NULL
pathways	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
274:19919-19924	NULL
,	NULL
1999	NULL
Khechai	NULL
F	NULL
,	NULL
Ollivier	NULL
V	NULL
,	NULL
Bridey	NULL
F	NULL
,	NULL
Amar	NULL
M	NULL
,	NULL
Hakim	NULL
J	NULL
,	NULL
de	NULL
Prost	NULL
D	NULL
:	NULL
Effect	NULL
of	NULL
advanced	NULL
glycation	NULL
end	NULL
product-modified	NULL
albumin	NULL
on	NULL
tissue	NULL
factor	NULL
expression	NULL
by	NULL
monocytes	NULL
:	NULL
role	NULL
of	NULL
oxidant	NULL
stress	NULL
and	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
.	NULL

Arterioscler	NULL
Thromb	NULL
Vase	NULL
Biol	NULL
17:2885-2890	NULL
,	NULL
1997	NULL
Santana	NULL
C	NULL
,	NULL
Noris	NULL
G	NULL
,	NULL
Espinoza	NULL
B	NULL
,	NULL
Ortega	NULL
E	NULL
:	NULL
Protein	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
leukocyte	NULL
activation	NULL
through	NULL
receptors	NULL
for	NULL
IgG	NULL
.	NULL

J	NULL
Leukoc	NULL
Biol	NULL
60:433-440	NULL
,	NULL
1996	NULL
Sanchez-Mejorada	NULL
G	NULL
,	NULL
Rosales	NULL
C	NULL
:	NULL
Foy	NULL
receptor-mediated	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
activation	NULL
in	NULL
monocytes	NULL
is	NULL
independent	NULL
of	NULL
Ras	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
273:27610-27619	NULL
,	NULL
1998	NULL
Fukazawa	NULL
T	NULL
,	NULL
Miyake	NULL
S	NULL
,	NULL
Band	NULL
V	NULL
,	NULL
Band	NULL
H	NULL
:	NULL
Tyrosine	NULL
phosphorylation	NULL
of	NULL
Cbl	NULL
upon	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
EGF	NULL
)	NULL
stimulation	NULL
and	NULL
its	NULL
association	NULL
with	NULL
EGF	NULL
receptor	NULL
and	NULL
downstream	NULL
signaling	NULL
proteins	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:14554-14559	NULL
,	NULL
1996	NULL
Lipson	NULL
KE	NULL
,	NULL
Pang	NULL
L	NULL
,	NULL
Huber	NULL
LJ	NULL
,	NULL
Chen	NULL
H	NULL
,	NULL
Tsai	NULL
JM	NULL
,	NULL
Hirth	NULL
P	NULL
,	NULL
Gazit	NULL
A	NULL
,	NULL
Levitzki	NULL
A	NULL
,	NULL
McMahon	NULL
G	NULL
:	NULL
Inhibition	NULL
of	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
and	NULL
epidermal	NULL
growth	NULL
factor	NULL
receptor	NULL
signaling	NULL
events	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
specific	NULL
synthetic	NULL
inhibitors	NULL
of	NULL
tyrosine	NULL
kinase	NULL
phosphorylation	NULL
.	NULL

J	NULL
Pharmacol	NULL
Exp	NULL
Ther	NULL
285:844-852	NULL
,	NULL
1998	NULL
Satoh	NULL
H	NULL
,	NULL
Togo	NULL
M	NULL
,	NULL
Hara	NULL
M	NULL
,	NULL
Miyata	NULL
T	NULL
,	NULL
Han	NULL
K	NULL
,	NULL
Mackawa	NULL
H	NULL
,	NULL
Ohno	NULL
M	NULL
,	NULL
Hashimoto	NULL
Y	NULL
,	NULL
Kurokawa	NULL
K	NULL
,	NULL
Watanabe	NULL
T	NULL
:	NULL
Advanced	NULL
glycation	NULL
endproducts	NULL
stimulate	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
and	NULL
proliferation	NULL
in	NULL
rabbit	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

Biockem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
239:111-115	NULL
,	NULL
1997	NULL
Simm	NULL
A	NULL
,	NULL
Munch	NULL
G	NULL
,	NULL
Seif	NULL
F	NULL
,	NULL
Schenk	NULL
O	NULL
,	NULL
Heidland	NULL
A	NULL
,	NULL
Richter	NULL
H	NULL
,	NULL
Vamvakas	NULL
S	NULL
,	NULL
Schinzel	NULL
R	NULL
:	NULL
Advanced	NULL
glycation	NULL
endproducts	NULL
stimulate	NULL
the	NULL
MAP-kinase	NULL
pathway	NULL
in	NULL
tubulus	NULL
cell	NULL
line	NULL
LLC-PK1L	NULL
.	NULL

FEBS	NULL
Lett	NULL
410:481-484	NULL
,	NULL
1997	NULL
Jiang	NULL
Y	NULL
,	NULL
Gram	NULL
H	NULL
,	NULL
Zhao	NULL
M	NULL
,	NULL
New	NULL
L	NULL
,	NULL
Gu	NULL
H	NULL
,	NULL
Feng	NULL
L	NULL
,	NULL
DiPadova	NULL
F	NULL
,	NULL
Ulevitch	NULL
RJ	NULL
,	NULL
Han	NULL
J	NULL
:	NULL
Characterization	NULL
of	NULL
the	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
the	NULL
fourth	NULL
member	NULL
of	NULL
p38	NULL
group	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
,	NULL
p388	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:30122-30128	NULL
,	NULL
1997	NULL
Taguchi	NULL
A	NULL
,	NULL
Blood	NULL
DC	NULL
,	NULL
del	NULL
Toro	NULL
G	NULL
,	NULL
Canet	NULL
A	NULL
,	NULL
Lee	NULL
DC	NULL
,	NULL
Qu	NULL
W	NULL
,	NULL
Tanji	NULL
N	NULL
,	NULL
Lu	NULL
Y	NULL
,	NULL
1504	NULL
51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

Lalla	NULL
E	NULL
,	NULL
Fu	NULL
C	NULL
,	NULL
Hofmann	NULL
MA	NULL
,	NULL
Kislinger	NULL
T	NULL
,	NULL
Ingram	NULL
M	NULL
,	NULL
Lu	NULL
A	NULL
,	NULL
Tanaka	NULL
H	NULL
,	NULL
Hori	NULL
O	NULL
,	NULL
Ogawa	NULL
S	NULL
,	NULL
Stern	NULL
DM	NULL
,	NULL
Schmidt	NULL
AM	NULL
:	NULL
Blockade	NULL
of	NULL
RAGE-amphoterin	NULL
signalling	NULL
suppresses	NULL
tumour	NULL
growth	NULL
and	NULL
metastases	NULL
.	NULL

Nature	NULL
405:354-360	NULL
,	NULL
2000	NULL
Li	NULL
N	NULL
,	NULL
Karin	NULL
M	NULL
;	NULL
:	NULL
Is	NULL
NF-	NULL
«	NULL
B	NULL
the	NULL
sensor	NULL
of	NULL
oxidative	NULL
stress	NULL
?	NULL

FASEB	NULL
J	NULL
18:1137-1148	NULL
,	NULL
1999	NULL
Bergmann	NULL
M	NULL
,	NULL
Hart	NULL
L	NULL
,	NULL
Lindsay	NULL
M	NULL
,	NULL
Barnes	NULL
PJ	NULL
,	NULL
Newton	NULL
R	NULL
:	NULL
Ix-B	NULL
«	NULL
degradation	NULL
and	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
are	NULL
insufficient	NULL
for	NULL
interleukin-16	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
-induced	NULL
«	NULL
B-dependent	NULL
transcription	NULL
:	NULL
requirement	NULL
for	NULL
an	NULL
additional	NULL
activation	NULL
pathway	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
273:6607-6610	NULL
,	NULL
1998	NULL
Wesselborg	NULL
S	NULL
,	NULL
Bauer	NULL
MKA	NULL
,	NULL
Vogt	NULL
M	NULL
,	NULL
Schmitz	NULL
ML	NULL
,	NULL
Schulze-Osthoff	NULL
K	NULL
:	NULL
Activation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
and	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
is	NULL
mediated	NULL
by	NULL
distinct	NULL
and	NULL
separate	NULL
stress	NULL
effector	NULL
pathways	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:12422-12429	NULL
,	NULL
1997	NULL
Carter	NULL
AB	NULL
,	NULL
Knudtson	NULL
KL	NULL
,	NULL
Monick	NULL
MM	NULL
,	NULL
Hunninghake	NULL
GW	NULL
:	NULL
The	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
is	NULL
required	NULL
for	NULL
NF-kB-dependent	NULL
gene	NULL
expres-sion	NULL
:	NULL
the	NULL
role	NULL
of	NULL
TATA-binding	NULL
protein	NULL
(	NULL
TBP	NULL
)	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
274:80858-30863	NULL
,	NULL
1999	NULL
Vanden-Berghe	NULL
W	NULL
,	NULL
Plaisance	NULL
S	NULL
,	NULL
Boone	NULL
E	NULL
,	NULL
De	NULL
Bosscher	NULL
K	NULL
,	NULL
Schmitz	NULL
ML	NULL
,	NULL
Fiers	NULL
W	NULL
,	NULL
Nishida	NULL
E	NULL
,	NULL
Matsumoto	NULL
K	NULL
:	NULL
P38	NULL
and	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathways	NULL
are	NULL
required	NULL
for	NULL
nuclear	NULL
fac-tor	NULL
«	NULL
B	NULL
p65	NULL
transactivation	NULL
mediated	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

Science	NULL
270:2008-2011	NULL
,	NULL
1995	NULL
Lee	NULL
JC	NULL
,	NULL
Kassis	NULL
S	NULL
,	NULL
Kumar	NULL
S	NULL
,	NULL
Badger	NULL
A	NULL
,	NULL
Adams	NULL
JL	NULL
:	NULL
P38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
:	NULL
mechanisms	NULL
and	NULL
therapeutic	NULL
potentials	NULL
.	NULL

Pharmacol	NULL
Ther	NULL
82:389-397	NULL
,	NULL
1999	NULL
Herlaar	NULL
E	NULL
,	NULL
Brown	NULL
Z	NULL
:	NULL
;	NULL
p38	NULL
MAPK	NULL
signalling	NULL
cascades	NULL
in	NULL
inflammatory	NULL
disease	NULL
.	NULL

Mol	NULL
Med	NULL
Today	NULL
5:439-447	NULL
,	NULL
1999	NULL
Salituro	NULL
FG	NULL
,	NULL
Germann	NULL
UA	NULL
,	NULL
Wilson	NULL
KP	NULL
,	NULL
Bemis	NULL
GW	NULL
,	NULL
Fox	NULL
T	NULL
,	NULL
Su	NULL
MS	NULL
:	NULL
Inhibitors	NULL
of	NULL
p38	NULL
MAP	NULL
kinase	NULL
:	NULL
therapeutic	NULL
intervention	NULL
in	NULL
cytokine-mediated	NULL
dis-eases	NULL
.	NULL

Curr	NULL
Med	NULL
Chem	NULL
6:807-8283	NULL
,	NULL
1999	NULL
Cain	NULL
BS	NULL
,	NULL
Meldrum	NULL
DR	NULL
,	NULL
Meng	NULL
X	NULL
,	NULL
Dinarello	NULL
CA	NULL
,	NULL
Shames	NULL
BD	NULL
,	NULL
Banerjee	NULL
A	NULL
,	NULL
Harken	NULL
AH	NULL
:	NULL
p38	NULL
MAPK	NULL
inhibition	NULL
decreases	NULL
TNF-	NULL
«	NULL
production	NULL
and	NULL
enhances	NULL
postischemic	NULL
human	NULL
myocardial	NULL
function	NULL
.	NULL

J	NULL
Surg	NULL
Res	NULL
83:7-12	NULL
,	NULL
1999	NULL
Degenhardt	NULL
TP	NULL
,	NULL
Grass	NULL
L	NULL
,	NULL
Reddy	NULL
S	NULL
,	NULL
Thorpe	NULL
SR	NULL
,	NULL
Diamandis	NULL
EP	NULL
,	NULL
Baynes	NULL
JW	NULL
:	NULL
Technical	NULL
note	NULL
:	NULL
the	NULL
serum	NULL
concentration	NULL
of	NULL
the	NULL
advanced	NULL
glycation	NULL
endproduct	NULL
N	NULL
epsilon-	NULL
(	NULL
carboxymethyl	NULL
)	NULL
lysine	NULL
is	NULL
increased	NULL
in	NULL
uremia	NULL
.	NULL

Kidney	NULL
Int	NULL
52:1064-1067	NULL
,	NULL
1997	NULL
DIABETES	NULL
,	NULL
VOL	NULL
.	NULL

50	NULL
,	NULL
JUNE	NULL
2001	NULL

